ALPHASUITEATLASTM
NR3C1 · P04150Homo sapiens
PROTEIN OVERVIEW

NR3C1Glucocorticoid receptor

P04150Homo sapiensReviewed · UniProt

Receptor for glucocorticoids (GC).

Sequence777 aa
Source mass85.66 kDa
Recorded PDB entries58
Isoforms listed16

UniProt locations Cytoplasm · Nucleus · Mitochondrion · Cytoplasm, cytoskeleton, spindle · Cytoplasm, cytoskeleton, microtubule organizing center, centrosome · Chromosome · Nucleus, nucleoplasm

01

Function

Receptor for glucocorticoids (GC) [103, 74]. Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors [73]. Affects inflammatory responses, cellular proliferation and differentiation in target tissues.

Involved in chromatin remodeling [22]. Plays a role in rapid mRNA degradation by binding to the 5' UTR of target mRNAs and interacting with PNRC2 in a ligand-dependent manner which recruits the RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leading to RNA decay [68]. Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth (By similarity)

By similarityExperimental evidence 5 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000250",
          "source": "UniProtKB",
          "id": "P06537"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "25775514"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "27120390"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "28139699"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "37478846"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "9590696"
        }
      ],
      "value": "Receptor for glucocorticoids (GC) (PubMed:27120390, PubMed:37478846). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors (PubMed:28139699). Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Involved in chromatin remodeling (PubMed:9590696). Plays a role in rapid mRNA degradation by binding to the 5' UTR of target mRNAs and interacting with PNRC2 in a ligand-dependent manner which recruits the RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leading to RNA decay (PubMed:25775514). Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth (By similarity)"
    }
  ],
  "commentType": "FUNCTION"
}
Isoform Alpha

Has transcriptional activation and repression activity [31, 94, 39, 96, 50, 49, 53, 56, 64]. Mediates glucocorticoid-induced apoptosis [61]. Promotes accurate chromosome segregation during mitosis [69].

May act as a tumor suppressor [69]. May play a negative role in adipogenesis through the regulation of lipolytic and antilipogenic gene expression (By similarity)

By similarityExperimental evidence 11 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000250",
          "source": "UniProtKB",
          "id": "P06537"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "11435610"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15769988"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15866175"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17635946"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "19141540"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "19248771"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "20484466"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "21664385"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "23303127"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "23820903"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "25847991"
        }
      ],
      "value": "Has transcriptional activation and repression activity (PubMed:11435610, PubMed:15769988, PubMed:15866175, PubMed:17635946, PubMed:19141540, PubMed:19248771, PubMed:20484466, PubMed:21664385, PubMed:23820903). Mediates glucocorticoid-induced apoptosis (PubMed:23303127). Promotes accurate chromosome segregation during mitosis (PubMed:25847991). May act as a tumor suppressor (PubMed:25847991). May play a negative role in adipogenesis through the regulation of lipolytic and antilipogenic gene expression (By similarity)"
    }
  ],
  "commentType": "FUNCTION",
  "molecule": "Isoform Alpha"
}
Isoform Beta

Acts as a dominant negative inhibitor of isoform Alpha [53, 18, 19]. Has intrinsic transcriptional activity independent of isoform Alpha when both isoforms are coexpressed [49, 67]. Loses this transcription modulator function on its own [53].

Has no hormone-binding activity [19]. May play a role in controlling glucose metabolism by maintaining insulin sensitivity (By similarity). Reduces hepatic gluconeogenesis through down-regulation of PEPCK in an isoform Alpha-dependent manner [67].

Directly regulates STAT1 expression in isoform Alpha-independent manner [67]

By similarityExperimental evidence 5 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000250",
          "source": "UniProtKB",
          "id": "P06537"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "19248771"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "20484466"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "26711253"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "7769088"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "8621628"
        }
      ],
      "value": "Acts as a dominant negative inhibitor of isoform Alpha (PubMed:20484466, PubMed:7769088, PubMed:8621628). Has intrinsic transcriptional activity independent of isoform Alpha when both isoforms are coexpressed (PubMed:19248771, PubMed:26711253). Loses this transcription modulator function on its own (PubMed:20484466). Has no hormone-binding activity (PubMed:8621628). May play a role in controlling glucose metabolism by maintaining insulin sensitivity (By similarity). Reduces hepatic gluconeogenesis through down-regulation of PEPCK in an isoform Alpha-dependent manner (PubMed:26711253). Directly regulates STAT1 expression in isoform Alpha-independent manner (PubMed:26711253)"
    }
  ],
  "commentType": "FUNCTION",
  "molecule": "Isoform Beta"
}
Isoform Alpha-2

Has lower transcriptional activation activity than isoform Alpha. Exerts a dominant negative effect on isoform Alpha trans-repression mechanism [53]

Evidence & references

No separate evidence record is supplied for this statement.

Complete source annotation
{
  "texts": [
    {
      "value": "Has lower transcriptional activation activity than isoform Alpha. Exerts a dominant negative effect on isoform Alpha trans-repression mechanism (PubMed:20484466)"
    }
  ],
  "commentType": "FUNCTION",
  "molecule": "Isoform Alpha-2"
}
Isoform GR-P

Increases activity of isoform Alpha

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "11358809"
        }
      ],
      "value": "Increases activity of isoform Alpha"
    }
  ],
  "commentType": "FUNCTION",
  "molecule": "Isoform GR-P"
}
Isoform Alpha-B

More effective than isoform Alpha in transcriptional activation, but not repression activity

Experimental evidence 2 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "11435610"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15866175"
        }
      ],
      "value": "More effective than isoform Alpha in transcriptional activation, but not repression activity"
    }
  ],
  "commentType": "FUNCTION",
  "molecule": "Isoform Alpha-B"
}
Isoform 10

Has transcriptional activation activity

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "20484466"
        }
      ],
      "value": "Has transcriptional activation activity"
    }
  ],
  "commentType": "FUNCTION",
  "molecule": "Isoform 10"
}
Isoform Alpha-C1

Has transcriptional activation activity

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15866175"
        }
      ],
      "value": "Has transcriptional activation activity"
    }
  ],
  "commentType": "FUNCTION",
  "molecule": "Isoform Alpha-C1"
}
Isoform Alpha-C2

Has transcriptional activation activity

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15866175"
        }
      ],
      "value": "Has transcriptional activation activity"
    }
  ],
  "commentType": "FUNCTION",
  "molecule": "Isoform Alpha-C2"
}
Isoform Alpha-C3

Has highest transcriptional activation activity of all isoforms created by alternative initiation [39, 64]. Has transcriptional repression activity [61]. Mediates glucocorticoid-induced apoptosis [61, 64]

Experimental evidence 3 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15866175"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "23303127"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "23820903"
        }
      ],
      "value": "Has highest transcriptional activation activity of all isoforms created by alternative initiation (PubMed:15866175, PubMed:23820903). Has transcriptional repression activity (PubMed:23303127). Mediates glucocorticoid-induced apoptosis (PubMed:23303127, PubMed:23820903)"
    }
  ],
  "commentType": "FUNCTION",
  "molecule": "Isoform Alpha-C3"
}
Isoform Alpha-D1

Has transcriptional activation activity

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15866175"
        }
      ],
      "value": "Has transcriptional activation activity"
    }
  ],
  "commentType": "FUNCTION",
  "molecule": "Isoform Alpha-D1"
}
Isoform Alpha-D2

Has transcriptional activation activity

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15866175"
        }
      ],
      "value": "Has transcriptional activation activity"
    }
  ],
  "commentType": "FUNCTION",
  "molecule": "Isoform Alpha-D2"
}
Isoform Alpha-D3

Has lowest transcriptional activation activity of all isoforms created by alternative initiation [39, 64]. Has transcriptional repression activity [61]

Experimental evidence 3 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15866175"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "23303127"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "23820903"
        }
      ],
      "value": "Has lowest transcriptional activation activity of all isoforms created by alternative initiation (PubMed:15866175, PubMed:23820903). Has transcriptional repression activity (PubMed:23303127)"
    }
  ],
  "commentType": "FUNCTION",
  "molecule": "Isoform Alpha-D3"
}

Additional functional context

Isoform Beta

High constitutive expression by neutrophils may provide a mechanism by which these cells escape glucocorticoid-induced cell death and up-regulation by pro-inflammatory cytokines such as IL8 further enhances their survival in the presence of glucocorticoids during inflammation

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "11238589"
        }
      ],
      "value": "High constitutive expression by neutrophils may provide a mechanism by which these cells escape glucocorticoid-induced cell death and up-regulation by pro-inflammatory cytokines such as IL8 further enhances their survival in the presence of glucocorticoids during inflammation"
    }
  ],
  "commentType": "MISCELLANEOUS",
  "molecule": "Isoform Beta"
}

Can up- or down-modulate aggregation and nuclear localization of expanded polyglutamine polypeptides derived from AR and HD through specific regulation of gene expression. Aggregation and nuclear localization of expanded polyglutamine proteins are regulated cellular processes that can be modulated by this receptor, a well-characterized transcriptional regulator

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "10639135"
        }
      ],
      "value": "Can up- or down-modulate aggregation and nuclear localization of expanded polyglutamine polypeptides derived from AR and HD through specific regulation of gene expression. Aggregation and nuclear localization of expanded polyglutamine proteins are regulated cellular processes that can be modulated by this receptor, a well-characterized transcriptional regulator"
    }
  ],
  "commentType": "MISCELLANEOUS"
}
Isoform Alpha

Predominant physiological form

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15866175"
        }
      ],
      "value": "Predominant physiological form"
    }
  ],
  "commentType": "MISCELLANEOUS",
  "molecule": "Isoform Alpha"
}
Isoform Alpha-2

Due to a partial intron retention

Curator inference
Evidence & references
  • ECO:0000305
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000305"
        }
      ],
      "value": "Due to a partial intron retention"
    }
  ],
  "commentType": "MISCELLANEOUS",
  "molecule": "Isoform Alpha-2"
}
Isoform Beta-2

Due to a partial intron retention

Curator inference
Evidence & references
  • ECO:0000305
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000305"
        }
      ],
      "value": "Due to a partial intron retention"
    }
  ],
  "commentType": "MISCELLANEOUS",
  "molecule": "Isoform Beta-2"
}
Isoform GR-A alpha

Lacks exons 5, 6 and 7. Found in glucocorticoid-resistant myeloma patients

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "8358712"
        }
      ],
      "value": "Lacks exons 5, 6 and 7. Found in glucocorticoid-resistant myeloma patients"
    }
  ],
  "commentType": "MISCELLANEOUS",
  "molecule": "Isoform GR-A alpha"
}
Isoform GR-A beta

Lacks exons 5, 6 and 7

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "8358712"
        }
      ],
      "value": "Lacks exons 5, 6 and 7"
    }
  ],
  "commentType": "MISCELLANEOUS",
  "molecule": "Isoform GR-A beta"
}
Isoform GR-P

Encoded by exons 2-7 plus several basepairs from the subsequent intron region. Lacks the ligand binding domain. Accounts for up to 10-20% of mRNAs

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "8358712"
        }
      ],
      "value": "Encoded by exons 2-7 plus several basepairs from the subsequent intron region. Lacks the ligand binding domain. Accounts for up to 10-20% of mRNAs"
    }
  ],
  "commentType": "MISCELLANEOUS",
  "molecule": "Isoform GR-P"
}
Isoform Alpha-B

Produced by alternative initiation at Met-27 of isoform Alpha

Curator inference
Evidence & references
  • ECO:0000305
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000305"
        }
      ],
      "value": "Produced by alternative initiation at Met-27 of isoform Alpha"
    }
  ],
  "commentType": "MISCELLANEOUS",
  "molecule": "Isoform Alpha-B"
}
Isoform Beta-B

Produced by alternative initiation at Met-27 of isoform Beta

Experimental evidenceCurator inference 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15866175"
        },
        {
          "evidenceCode": "ECO:0000305"
        }
      ],
      "value": "Produced by alternative initiation at Met-27 of isoform Beta"
    }
  ],
  "commentType": "MISCELLANEOUS",
  "molecule": "Isoform Beta-B"
}
Isoform Alpha-C1

Produced by alternative initiation at Met-86 of isoform Alpha

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15866175"
        }
      ],
      "value": "Produced by alternative initiation at Met-86 of isoform Alpha"
    }
  ],
  "commentType": "MISCELLANEOUS",
  "molecule": "Isoform Alpha-C1"
}
Isoform Alpha-C2

Produced by alternative initiation at Met-90 of isoform Alpha

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15866175"
        }
      ],
      "value": "Produced by alternative initiation at Met-90 of isoform Alpha"
    }
  ],
  "commentType": "MISCELLANEOUS",
  "molecule": "Isoform Alpha-C2"
}
Isoform Alpha-C3

Produced by alternative initiation at Met-98 of isoform Alpha

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15866175"
        }
      ],
      "value": "Produced by alternative initiation at Met-98 of isoform Alpha"
    }
  ],
  "commentType": "MISCELLANEOUS",
  "molecule": "Isoform Alpha-C3"
}
Isoform Alpha-D1

Produced by alternative initiation at Met-316 of isoform Alpha

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15866175"
        }
      ],
      "value": "Produced by alternative initiation at Met-316 of isoform Alpha"
    }
  ],
  "commentType": "MISCELLANEOUS",
  "molecule": "Isoform Alpha-D1"
}
Isoform Alpha-D2

Produced by alternative initiation at Met-331 of isoform Alpha

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15866175"
        }
      ],
      "value": "Produced by alternative initiation at Met-331 of isoform Alpha"
    }
  ],
  "commentType": "MISCELLANEOUS",
  "molecule": "Isoform Alpha-D2"
}
Isoform Alpha-D3

Produced by alternative initiation at Met-336 of isoform Alpha

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15866175"
        }
      ],
      "value": "Produced by alternative initiation at Met-336 of isoform Alpha"
    }
  ],
  "commentType": "MISCELLANEOUS",
  "molecule": "Isoform Alpha-D3"
}

GO functions & biological processes

RNA polymerase II transcription regulatory region sequence-specific DNA bindingenablesUniProtKB:P04150
GO
GO:0000977 · evidence & context
RNA polymerase II cis-regulatory region sequence-specific DNA bindingenablesUniProtKB:P04150
GO
GO:0000978 · evidence & context
DNA-binding transcription factor activity, RNA polymerase II-specificenablesUniProtKB:P04150
GO
GO:0000981 · evidence & context
  • ECO:0005556 GO_REF:0000113 ISA · NTNU_SB · 20190405
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "tfclass", "id": "2.1.1"}]}]
core promoter sequence-specific DNA bindingenablesUniProtKB:P04150 · Context-qualified assertion; see evidence
GO
GO:0001046 · evidence & context
  • ECO:0000314 PMID:17081986 ↗ IDA · CAFA · 20191205
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q99576", "relation": "has_input"}]}]
DNA-binding transcription repressor activity, RNA polymerase II-specificenablesUniProtKB:P04150
GO
GO:0001227 · evidence & context
All recorded function and process assertions (53)
DNA-binding transcription activator activity, RNA polymerase II-specificenablesUniProtKB:P04150
GO
GO:0001228 · evidence & context
DNA-binding transcription activator activity, RNA polymerase II-specificenablesUniProtKB:P04150 · Context-qualified assertion; see evidence
GO
GO:0001228 · evidence & context
  • ECO:0000314 PMID:23823477 ↗ IDA · UniProt · 20220204
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q8TAP4", "relation": "has_input"}]}]
DNA-binding transcription activator activity, RNA polymerase II-specificenablesUniProtKB:P04150 · Context-qualified assertion; see evidence
GO
GO:0001228 · evidence & context
  • ECO:0000314 PMID:28139699 ↗ IDA · UniProt · 20221212
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "0071385", "relation": "part_of"}, {"db": "GO", "id": "0005634", "relation": "occurs_in"}]}]
DNA bindingenablesUniProtKB:P04150
GO
GO:0003677 · evidence & context
  • ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260727
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}, {"connectedXrefs": [{"db": "InterPro", "id": "IPR001409"}]}]
DNA-binding transcription factor activityenablesUniProtKB:P04150
GO
GO:0003700 · evidence & context
  • ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR001628"}]}]
  • ECO:0000304 PMID:10903900 ↗ TAS · PINC · 20030904
    qualifier: enables
  • ECO:0000314 PMID:15769988 ↗ IDA · UniProt · 20141124
    qualifier: enables
  • ECO:0000304 PMID:7769088 ↗ TAS · PINC · 20030904
    qualifier: enables
nuclear steroid receptor activityenablesUniProtKB:P04150
GO
GO:0003707 · evidence & context
  • ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00089151"}]}]
nuclear receptor activityenablesUniProtKB:P04150
GO
GO:0004879 · evidence & context
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20250904
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "FB", "id": "FBgn0264562"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1346832"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1352467"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:88064"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:95824"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:97567"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN002377694"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2147"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2581"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2582"}]}, {"connectedXrefs": [{"db": "RGD", "id": "3094"}]}, {"connectedXrefs": [{"db": "RGD", "id": "3317"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P03372"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P04150"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P06212"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P06401"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P10275"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q92731"}]}, {"connectedXrefs": [{"db": "ZFIN", "id": "ZDB-GENE-020806-5"}]}, {"connectedXrefs": [{"db": "ZFIN", "id": "ZDB-GENE-030116-1"}]}, {"connectedXrefs": [{"db": "ZFIN", "id": "ZDB-GENE-030116-2"}]}, {"connectedXrefs": [{"db": "ZFIN", "id": "ZDB-GENE-050522-503"}]}, {"connectedXrefs": [{"db": "ZFIN", "id": "ZDB-GENE-060131-1"}]}, {"connectedXrefs": [{"db": "ZFIN", "id": "ZDB-GENE-060531-23"}]}, {"connectedXrefs": [{"db": "ZFIN", "id": "ZDB-GENE-990415-214"}]}]
  • ECO:0000314 PMID:17635946 ↗ IDA · UniProt · 20180525
    qualifier: enables
nuclear glucocorticoid receptor activityenablesUniProtKB:P04150
GO
GO:0004883 · evidence & context
  • ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260727
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}, {"connectedXrefs": [{"db": "InterPro", "id": "IPR001409"}]}]
  • ECO:0000304 PMID:8621628 ↗ TAS · PINC · 20030904
    qualifier: enables
steroid bindingenablesUniProtKB:P04150
GO
GO:0005496 · evidence & context
  • ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR001409"}]}]
  • ECO:0000314 PMID:15769988 ↗ IDA · UniProt · 20141124
    qualifier: enables
protein bindingenablesUniProtKB:P04150
GO
GO:0005515 · evidence & context
  • ECO:0000353 PMID:10364267 ↗ IPI · UniProt · 20050927
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P48552"}]}]
  • ECO:0000353 PMID:11266503 ↗ IPI · UniProt · 20050927
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P48552"}]}]
  • ECO:0000353 PMID:12552091 ↗ IPI · BHF-UCL · 20081209
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P51692"}]}]
  • ECO:0000353 PMID:12773562 ↗ IPI · UniProt · 20050927
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P48552"}]}]
  • ECO:0000353 PMID:12902338 ↗ IPI · CAFA · 20160822
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P84022"}]}]
  • ECO:0000353 PMID:15591535 ↗ IPI · UniProt · 20150619
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P22829"}]}]
  • ECO:0000353 PMID:15591535 ↗ IPI · UniProt · 20150619
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P51179"}]}]
  • ECO:0000353 PMID:15591535 ↗ IPI · UniProt · 20150619
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q06219"}]}]
  • ECO:0000353 PMID:15769988 ↗ IPI · UniProt · 20141124
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y3R0"}]}]
  • ECO:0000353 PMID:15941832 ↗ IPI · HGNC-UCL · 20050627
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O94992"}]}]
  • ECO:0000353 PMID:16606617 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P59598"}]}]
  • ECO:0000353 PMID:16619302 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q62667"}]}]
  • ECO:0000353 PMID:16888650 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P01730"}]}]
  • ECO:0000353 PMID:16888650 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06239"}]}]
  • ECO:0000353 PMID:17003263 ↗ IPI · UniProt · 20100624
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P68036"}]}]
  • ECO:0000353 PMID:17635946 ↗ IPI · UniProt · 20141124
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y3R0"}]}]
  • ECO:0000353 PMID:19141540 ↗ IPI · UniProt · 20140223
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O08785"}]}]
  • ECO:0000353 PMID:19841061 ↗ IPI · DisProt · 20230112
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P12931"}, {"db": "UniProtKB", "id": "Q92793"}]}]
  • ECO:0000353 PMID:20195357 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P07900"}]}]
  • ECO:0000353 PMID:20195357 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P82094"}]}]
  • ECO:0000353 PMID:20195357 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q6ZU52"}]}]
  • ECO:0000353 PMID:20211142 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P28702"}]}]
  • ECO:0000353 PMID:21980503 ↗ IPI · UniProt · 20140223
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O15516"}]}]
  • ECO:0000353 PMID:22170608 ↗ IPI · UniProt · 20140430
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P97784"}]}]
  • ECO:0000353 PMID:22170608 ↗ IPI · UniProt · 20140430
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9R194"}]}]
  • ECO:0000353 PMID:24291004 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P31749"}]}]
  • ECO:0000353 PMID:24658140 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P00533"}]}]
  • ECO:0000353 PMID:24949977 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P07900"}]}]
  • ECO:0000353 PMID:27353360 ↗ IPI · UniProt · 20161004
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q8TF40"}]}]
  • ECO:0000353 PMID:27353360 ↗ IPI · UniProt · 20161004
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9P278"}]}]
  • ECO:0000353 PMID:31467278 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P07900"}]}]
  • ECO:0000353 PMID:31980649 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P00533"}]}]
  • ECO:0000353 PMID:32814053 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O95416"}]}]
  • ECO:0000353 PMID:32814053 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q14141"}]}]
  • ECO:0000353 PMID:9079630 ↗ IPI · UniProt · 20051118
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q04917"}]}]
protein bindingenablesUniProtKB:P04150 · Context-qualified assertion; see evidence
GO
GO:0005515 · evidence & context
  • ECO:0000353 PMID:17978169 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P41235"}]}]
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "0005634", "relation": "occurs_in"}]}]
zinc ion bindingenablesUniProtKB:P04150
GO
GO:0008270 · evidence & context
  • ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR001628"}]}, {"connectedXrefs": [{"db": "InterPro", "id": "IPR013088"}]}]
TBP-class protein bindingenablesUniProtKB:P04150
GO
GO:0017025 · evidence & context
  • ECO:0000353 PMID:19841061 ↗ IPI · DisProt · 20230112
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P20226"}]}]
protein kinase bindingenablesUniProtKB:P04150
GO
GO:0019901 · evidence & context
  • ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260724
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00028598"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
  • ECO:0000353 PMID:20371704 ↗ IPI · ARUK-UCL · 20171027
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P49840"}]}]
estrogen response element bindingenablesUniProtKB:P04150
GO
GO:0034056 · evidence & context
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20221130
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "MGI", "id": "MGI:1347056"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN001182563"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2582"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P03372"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q92731"}]}]
identical protein bindingenablesUniProtKB:P04150
GO
GO:0042802 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
sequence-specific DNA bindingenablesUniProtKB:P04150
GO
GO:0043565 · evidence & context
  • ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260727
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}, {"connectedXrefs": [{"db": "InterPro", "id": "IPR001628"}]}]
Hsp90 protein bindingenablesUniProtKB:P04150
GO
GO:0051879 · evidence & context
  • ECO:0000353 PMID:26593036 ↗ IPI · UniProt · 20170317
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q18688"}]}]
steroid hormone bindingenablesUniProtKB:P04150
GO
GO:1990239 · evidence & context
sequence-specific double-stranded DNA bindingenablesUniProtKB:P04150
GO
GO:1990837 · evidence & context
  • ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00028376"}]}]
  • ECO:0000314 PMID:28473536 ↗ IDA · ARUK-UCL · 20200608
    qualifier: enables
promoter-specific chromatin bindingenablesUniProtKB:P04150
GO
GO:1990841 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
negative regulation of transcription by RNA polymerase IIinvolved inUniProtKB:P04150
GO
GO:0000122 · evidence & context
regulation of DNA-templated transcriptioninvolved inUniProtKB:P04150
GO
GO:0006355 · evidence & context
  • ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR001409"}]}, {"connectedXrefs": [{"db": "InterPro", "id": "IPR001628"}]}, {"connectedXrefs": [{"db": "InterPro", "id": "IPR013088"}]}]
  • ECO:0000314 PMID:19141540 ↗ IDA · UniProt · 20140223
    qualifier: involved_in
regulation of DNA-templated transcriptioninvolved inUniProtKB:P04150 · Context-qualified assertion; see evidence
GO
GO:0006355 · evidence & context
  • ECO:0000314 PMID:17081986 ↗ IDA · CAFA · 20200501
    qualifier: involved_in
    extensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q99576", "relation": "has_input"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "O60779", "relation": "has_input"}]}]
regulation of transcription by RNA polymerase IIinvolved inUniProtKB:P04150
GO
GO:0006357 · evidence & context
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20241121
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "FB", "id": "FBgn0035849"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1346831"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1346832"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1347056"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1352459"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1352467"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:88064"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN001182563"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2582"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2741"}]}, {"connectedXrefs": [{"db": "RGD", "id": "3094"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P03372"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P04150"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P06401"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P10275"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q92731"}]}]
signal transductioninvolved inUniProtKB:P04150
GO
GO:0007165 · evidence & context
microglia differentiationinvolved inUniProtKB:P04150
GO
GO:0014004 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
nuclear receptor-mediated steroid hormone signaling pathwayinvolved inUniProtKB:P04150
GO
GO:0030518 · evidence & context
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20240802
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "MGI", "id": "MGI:95824"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN002786985"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2741"}]}]
nuclear receptor-mediated corticosteroid signaling pathwayinvolved inUniProtKB:P04150
GO
GO:0031958 · evidence & context
  • ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00086690"}]}]
synaptic transmission, glutamatergicinvolved inUniProtKB:P04150
GO
GO:0035249 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
nuclear receptor-mediated glucocorticoid signaling pathwayinvolved inUniProtKB:P04150
GO
GO:0042921 · evidence & context
  • ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR001409"}]}]
negative regulation of DNA-templated transcriptioninvolved inUniProtKB:P04150
GO
GO:0045892 · evidence & context
positive regulation of DNA-templated transcriptioninvolved inUniProtKB:P04150
GO
GO:0045893 · evidence & context
  • ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00029082"}]}]
positive regulation of transcription by RNA polymerase IIinvolved inUniProtKB:P04150
GO
GO:0045944 · evidence & context
positive regulation of transcription by RNA polymerase IIinvolved inUniProtKB:P04150 · Context-qualified assertion; see evidence
GO
GO:0045944 · evidence & context
  • ECO:0000314 PMID:16728402 ↗ IDA · NTNU_SB · 20140323
    qualifier: involved_in
    extensions: [{"connectedXrefs": [{"db": "NCBI_Gene", "id": "4128", "relation": "has_input"}]}]
positive regulation of transcription by RNA polymerase IIinvolved inUniProtKB:P04150 · Context-qualified assertion; see evidence
GO
GO:0045944 · evidence & context
  • ECO:0000314 PMID:23823477 ↗ IDA · UniProt · 20140915
    qualifier: involved_in
    extensions: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q8TAP4", "relation": "has_input"}]}]
astrocyte differentiationinvolved inUniProtKB:P04150
GO
GO:0048708 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
response to glucocorticoidinvolved inUniProtKB:P04150
GO
GO:0051384 · evidence & context
  • ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00089100"}]}]
motor behaviorinvolved inUniProtKB:P04150
GO
GO:0061744 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
cellular response to steroid hormone stimulusinvolved inUniProtKB:P04150
GO
GO:0071383 · evidence & context
cellular response to glucocorticoid stimulusinvolved inUniProtKB:P04150
GO
GO:0071385 · evidence & context
cellular response to dexamethasone stimulusinvolved inUniProtKB:P04150
GO
GO:0071549 · evidence & context
cellular response to transforming growth factor beta stimulusinvolved inUniProtKB:P04150
GO
GO:0071560 · evidence & context
motor neuron apoptotic processinvolved inUniProtKB:P04150
GO
GO:0097049 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
neuroinflammatory responseinvolved inUniProtKB:P04150
GO
GO:0150076 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
response to ketoneinvolved inUniProtKB:P04150
GO
GO:1901654 · evidence & context
  • ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00090656"}]}]
positive regulation of miRNA transcriptioninvolved inUniProtKB:P04150
GO
GO:1902895 · evidence & context
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
positive regulation of miRNA transcriptioninvolved inUniProtKB:P04150 · Context-qualified assertion; see evidence
GO
GO:1902895 · evidence & context
  • ECO:0000314 PMID:27334923 ↗ IDA · ARUK-UCL · 20210108
    qualifier: involved_in
    extensions: [{"connectedXrefs": [{"db": "RNAcentral", "id": "URS00006BADF6_9606", "relation": "has_input"}]}]
02

Names & Taxonomy

Recommended name
Glucocorticoid receptor
Gene
NR3C1
Accession / entry
P04150 · GCR_HUMAN
Species
Homo sapiens · NCBI 9606
Recorded aliases
GRL · Nuclear receptor subfamily 3 group C member 1
Full taxonomy & recorded names

Eukaryota → Metazoa → Chordata → Craniata → Vertebrata → Euteleostomi → Mammalia → Eutheria → Euarchontoglires → Primates → Haplorrhini → Catarrhini → Hominidae → Homo

{
  "names": {
    "recommendedName": {
      "fullName": {
        "value": "Glucocorticoid receptor"
      },
      "shortNames": [
        {
          "value": "GR"
        }
      ]
    },
    "alternativeNames": [
      {
        "fullName": {
          "value": "Nuclear receptor subfamily 3 group C member 1"
        }
      }
    ]
  },
  "genes": [
    {
      "geneName": {
        "evidences": [
          {
            "evidenceCode": "ECO:0000312",
            "source": "HGNC",
            "id": "HGNC:7978"
          }
        ],
        "value": "NR3C1"
      },
      "synonyms": [
        {
          "value": "GRL"
        }
      ]
    }
  ]
}
03

Subcellular Location

UniProt locations and GO cellular-component assertions. Relations and contexts remain distinct; “part of” is not automatically a residence claim.

CytoplasmReported location

Isoform Alpha

After ligand activation, translocates from the cytoplasm to the nucleus [104]. The hormone-occupied receptor undergoes rapid exchange between chromatin and the nucleoplasmic compartment (By similarity). In the presence of NR1D1 shows a time-dependent subcellular localization, localizing to the cytoplasm at ZT8 and to the nucleus at ZT20 (By similarity). Lacks this diurnal pattern of localization in the absence of NR1D1, localizing to both nucleus and the cytoplasm at ZT8 and ZT20 (By similarity). Upon dexamethasone binding associates with the glucocorticoid response elements of target genes (By similarity)

UniProt
Experimental evidence 6 publications
Evidence & references
NucleusReported location

Isoform Alpha

After ligand activation, translocates from the cytoplasm to the nucleus [104]. The hormone-occupied receptor undergoes rapid exchange between chromatin and the nucleoplasmic compartment (By similarity). In the presence of NR1D1 shows a time-dependent subcellular localization, localizing to the cytoplasm at ZT8 and to the nucleus at ZT20 (By similarity). Lacks this diurnal pattern of localization in the absence of NR1D1, localizing to both nucleus and the cytoplasm at ZT8 and ZT20 (By similarity). Upon dexamethasone binding associates with the glucocorticoid response elements of target genes (By similarity)

UniProt
Experimental evidence 6 publications
Evidence & references
MitochondrionReported location

Isoform Alpha

After ligand activation, translocates from the cytoplasm to the nucleus [104]. The hormone-occupied receptor undergoes rapid exchange between chromatin and the nucleoplasmic compartment (By similarity). In the presence of NR1D1 shows a time-dependent subcellular localization, localizing to the cytoplasm at ZT8 and to the nucleus at ZT20 (By similarity). Lacks this diurnal pattern of localization in the absence of NR1D1, localizing to both nucleus and the cytoplasm at ZT8 and ZT20 (By similarity). Upon dexamethasone binding associates with the glucocorticoid response elements of target genes (By similarity)

UniProt
Experimental evidence 1 publication
Evidence & references
Cytoplasm, cytoskeleton, spindleReported location

Isoform Alpha

After ligand activation, translocates from the cytoplasm to the nucleus [104]. The hormone-occupied receptor undergoes rapid exchange between chromatin and the nucleoplasmic compartment (By similarity). In the presence of NR1D1 shows a time-dependent subcellular localization, localizing to the cytoplasm at ZT8 and to the nucleus at ZT20 (By similarity). Lacks this diurnal pattern of localization in the absence of NR1D1, localizing to both nucleus and the cytoplasm at ZT8 and ZT20 (By similarity). Upon dexamethasone binding associates with the glucocorticoid response elements of target genes (By similarity)

UniProt
Experimental evidence 1 publication
Evidence & references
Cytoplasm, cytoskeleton, microtubule organizing center, centrosomeReported location

Isoform Alpha

After ligand activation, translocates from the cytoplasm to the nucleus [104]. The hormone-occupied receptor undergoes rapid exchange between chromatin and the nucleoplasmic compartment (By similarity). In the presence of NR1D1 shows a time-dependent subcellular localization, localizing to the cytoplasm at ZT8 and to the nucleus at ZT20 (By similarity). Lacks this diurnal pattern of localization in the absence of NR1D1, localizing to both nucleus and the cytoplasm at ZT8 and ZT20 (By similarity). Upon dexamethasone binding associates with the glucocorticoid response elements of target genes (By similarity)

UniProt
Experimental evidence 1 publication
Evidence & references
ChromosomeReported location

Isoform Alpha

After ligand activation, translocates from the cytoplasm to the nucleus [104]. The hormone-occupied receptor undergoes rapid exchange between chromatin and the nucleoplasmic compartment (By similarity). In the presence of NR1D1 shows a time-dependent subcellular localization, localizing to the cytoplasm at ZT8 and to the nucleus at ZT20 (By similarity). Lacks this diurnal pattern of localization in the absence of NR1D1, localizing to both nucleus and the cytoplasm at ZT8 and ZT20 (By similarity). Upon dexamethasone binding associates with the glucocorticoid response elements of target genes (By similarity)

UniProt
By similarity
Evidence & references
  • ECO:0000250 UniProtKB:P06537
Nucleus, nucleoplasmReported location

Isoform Alpha

After ligand activation, translocates from the cytoplasm to the nucleus [104]. The hormone-occupied receptor undergoes rapid exchange between chromatin and the nucleoplasmic compartment (By similarity). In the presence of NR1D1 shows a time-dependent subcellular localization, localizing to the cytoplasm at ZT8 and to the nucleus at ZT20 (By similarity). Lacks this diurnal pattern of localization in the absence of NR1D1, localizing to both nucleus and the cytoplasm at ZT8 and ZT20 (By similarity). Upon dexamethasone binding associates with the glucocorticoid response elements of target genes (By similarity)

UniProt
By similarity
Evidence & references
  • ECO:0000250 UniProtKB:P06537
NucleusReported location

Isoform Beta

Expressed predominantly in the nucleus with some expression also detected in the cytoplasm

UniProt
Experimental evidence 3 publications
Evidence & references
All recorded location assertions (27)
CytoplasmReported location

Isoform Beta

Expressed predominantly in the nucleus with some expression also detected in the cytoplasm

UniProt
Experimental evidence 2 publications
Evidence & references
NucleusReported location

Isoform Alpha-B

After ligand activation, translocates from the cytoplasm to the nucleus

UniProt
Experimental evidence 1 publication
Evidence & references
CytoplasmReported location

Isoform Alpha-B

After ligand activation, translocates from the cytoplasm to the nucleus

UniProt
Experimental evidence 1 publication
Evidence & references
chromatinis active in
GO
Evidence & references
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20250413
    qualifier: is_active_in
    withFrom: [{"connectedXrefs": [{"db": "PANTHER", "id": "PTN002377694"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2741"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P03372"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P06401"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P07812"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P10275"}]}]
nucleusis active in
GO
1 publication
Evidence & references
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20260601
    qualifier: is_active_in
    withFrom: [{"connectedXrefs": [{"db": "FB", "id": "FBgn0264562"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:109392"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1346831"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1346832"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:1352467"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:88064"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:95824"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN001182563"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2147"}]}, {"connectedXrefs": [{"db": "RGD", "id": "2581"}]}, {"connectedXrefs": [{"db": "RGD", "id": "3094"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "A0A1D5PRD7"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "O95718"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P03372"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P04150"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P06212"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P07812"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P08235"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P10275"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P11474"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P49884"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P70033"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q15406"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q92731"}]}, {"connectedXrefs": [{"db": "ZFIN", "id": "ZDB-GENE-050522-503"}]}]
  • ECO:0000314 PMID:28139699 ↗ IDA · UniProt · 20221212
    qualifier: is_active_in
chromatinlocated in
GO
Evidence & references
  • ECO:0005556 GO_REF:0000113 ISA · NTNU_SB · 20190405
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "tfclass", "id": "2.1.1"}]}]
nucleuslocated in
GO
Curator inferenceExperimental evidence 10 publications
Evidence & references
  • ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260727
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00026330"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}, {"connectedXrefs": [{"db": "InterPro", "id": "IPR001409"}]}, {"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0191"}]}]
  • ECO:0000314 PMID:15769988 ↗ IDA · UniProt · 20141124
    qualifier: located_in
  • ECO:0000314 PMID:17635946 ↗ IDA · UniProt · 20141124
    qualifier: located_in
  • ECO:0000305 PMID:1894621 ↗ IC · UniProt · 20191022
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "GO", "id": "0045892"}]}]
  • ECO:0000314 PMID:22022502 ↗ IDA · UniProt · 20161011
    qualifier: located_in
  • ECO:0000314 PMID:23878391 ↗ IDA · MGI · 20140926
    qualifier: located_in
  • ECO:0000269 PMID:27120390 ↗ EXP · UniProt · 20240916
    qualifier: located_in
  • ECO:0000269 PMID:30698747 ↗ EXP · UniProt · 20240916
    qualifier: located_in
  • ECO:0000269 PMID:8621628 ↗ EXP · UniProt · 20240916
    qualifier: located_in
  • ECO:0000314 PMID:9353307 ↗ IDA · UniProt · 20170821
    qualifier: located_in
  • ECO:0000304 PMID:9873044 ↗ TAS · PINC · 20030904
    qualifier: located_in
nucleoplasmlocated in
GO
Evidence & references
  • ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0190"}]}]
  • ECO:0000314 GO_REF:0000052 IDA · HPA · 20251115
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-376419 TAS · Reactome · 20130226
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-382096 TAS · Reactome · 20130226
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-4341025 TAS · Reactome · 20160716
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5618080 TAS · Reactome · 20130516
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-5618093 TAS · Reactome · 20130516
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-8856930 TAS · Reactome · 20130516
    qualifier: located_in
chromosomelocated in
GO
By similarity
Evidence & references
  • ECO:0000250 GO_REF:0000024 ISS · UniProt · 20240916
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}]
  • ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0468"}]}]
cytoplasmlocated in
GO
Experimental evidence 7 publications
Evidence & references
  • ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260727
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}, {"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0086"}]}]
  • ECO:0000314 PMID:15769988 ↗ IDA · UniProt · 20141124
    qualifier: located_in
  • ECO:0000314 PMID:17635946 ↗ IDA · UniProt · 20141124
    qualifier: located_in
  • ECO:0000314 PMID:22022502 ↗ IDA · UniProt · 20161011
    qualifier: located_in
  • ECO:0000269 PMID:27120390 ↗ EXP · UniProt · 20240916
    qualifier: located_in
  • ECO:0000269 PMID:30698747 ↗ EXP · UniProt · 20240916
    qualifier: located_in
  • ECO:0000269 PMID:8621628 ↗ EXP · UniProt · 20240916
    qualifier: located_in
  • ECO:0000304 PMID:9873044 ↗ TAS · PINC · 20030904
    qualifier: located_in
mitochondrionlocated in
GO
Evidence & references
  • ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0173"}]}]
  • ECO:0000314 GO_REF:0000052 IDA · HPA · 20251115
    qualifier: located_in
mitochondrial matrixlocated in
GO
1 publication
Evidence & references
centrosomelocated in
GO
Evidence & references
  • ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0048"}]}]
spindlelocated in
GO
Evidence & references
  • ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0251"}]}]
cytosollocated in
GO
Evidence & references
  • ECO:0000314 GO_REF:0000052 IDA · HPA · 20251115
    qualifier: located_in
  • ECO:0000501 GO_REF:0000120 IEA · UniProt · 20260724
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00029243"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
  • ECO:0000304 Reactome:R-HSA-5618080 TAS · Reactome · 20160716
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9678925 TAS · Reactome · 20160716
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-9690534 TAS · Reactome · 20160716
    qualifier: located_in
membranelocated in
GO
Evidence & references
  • ECO:0000265 GO_REF:0000107 IEA · Ensembl · 20260724
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P06537"}]}, {"connectedXrefs": [{"db": "ensembl", "id": "ENSMUSP00000111229"}]}]
nuclear specklocated in
GO
1 publication
Evidence & references
synapselocated in
GO
Evidence & references
  • ECO:0000366 GO_REF:0000108 IEA · GOC · 20260727
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "GO", "id": "0035249"}]}]
protein-containing complexpart of
GO
1 publication
Evidence & references

Membrane topology 0

No annotation is recorded in this UniProt entry.

04

Disease & Variants

Source annotations; a recorded variant is not automatically a clinical classification.

Glucocorticoid resistance, generalized GCCR

An autosomal dominant disease characterized by increased plasma cortisol concentration and high urinary free cortisol, resistance to adrenal suppression by dexamethasone, and the absence of Cushing syndrome typical signs. Clinical features include hypoglycemia, hypertension, metabolic alkalosis, chronic fatigue and profound anxiety.

Experimental evidence 14 publications
Evidence & references

The disease is caused by variants affecting the gene represented in this entry

Evidence & references

No separate evidence record is supplied for this statement.

Complete source annotation
{
  "commentType": "DISEASE",
  "disease": {
    "diseaseId": "Glucocorticoid resistance, generalized",
    "diseaseAccession": "DI-04226",
    "acronym": "GCCR",
    "description": "An autosomal dominant disease characterized by increased plasma cortisol concentration and high urinary free cortisol, resistance to adrenal suppression by dexamethasone, and the absence of Cushing syndrome typical signs. Clinical features include hypoglycemia, hypertension, metabolic alkalosis, chronic fatigue and profound anxiety.",
    "diseaseCrossReference": {
      "database": "MIM",
      "id": "615962"
    },
    "evidences": [
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "11589680"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "11701741"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "12050230"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "15769988"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "1704018"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "17635946"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "20335448"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "21362280"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "23426617"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "24483153"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "26031419"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "26541474"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "27120390"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "7683692"
      }
    ]
  },
  "note": {
    "texts": [
      {
        "value": "The disease is caused by variants affecting the gene represented in this entry"
      }
    ]
  }
}

Polymorphism notes

Carriers of the 22-Glu-Lys-23 allele are relatively more resistant to the effects of GCs with respect to the sensitivity of the adrenal feedback mechanism than non-carriers, resulting in a better metabolic health profile. Carriers have a better survival than non-carriers, as well as lower serum CRP levels. The 22-Glu-Lys-23 polymorphism is associated with a sex-specific, beneficial body composition at young-adult age, as well as greater muscle strength in males

Evidence & references

No separate evidence record is supplied for this statement.

Complete source annotation
{
  "texts": [
    {
      "value": "Carriers of the 22-Glu-Lys-23 allele are relatively more resistant to the effects of GCs with respect to the sensitivity of the adrenal feedback mechanism than non-carriers, resulting in a better metabolic health profile. Carriers have a better survival than non-carriers, as well as lower serum CRP levels. The 22-Glu-Lys-23 polymorphism is associated with a sex-specific, beneficial body composition at young-adult age, as well as greater muscle strength in males"
    }
  ],
  "commentType": "POLYMORPHISM"
}

Natural variants 28

Scroll across the table for evidence and actions.

28 recorded rows

FeaturePositionDescriptionEvidenceInspect
R23KVAR_01414023reduces transactivation activity; does not affect transrepression activity; dbSNP:rs6190
R → K
Experimental evidence 7 publications
Evidence & references
No verified residues in this structure
F29LVAR_01562829in dbSNP:rs148102613
F → L
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
F65VVAR_01462265in dbSNP:rs6192
F → V
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
N72DVAR_07579772associated in cis with A-321 and S-766 in one individual; doubles transactivation potential
N → D
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
L112FVAR_015629112in dbSNP:rs542110718
L → F
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
D233NVAR_015630233in dbSNP:rs1241576112
D → N
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
V321AVAR_075798321associated in cis with D-72 and S-766 in one individual; doubles transactivation potential
V → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
N363SVAR_004675363enhances transactivation activity; does not affect transrepression activity; may increase sensitivity to exogenously administered glucocorticoids; may contribute to central obesity in men and show lack of association with other risk factors for coronary heart disease and diabetes mellitus; dbSNP:rs56149945
N → S
Experimental evidence 6 publications
Evidence & references
No verified residues in this structure
C421YVAR_015631421Natural variant
C → Y
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
V423AVAR_075799423in GCCR; uncertain significance; reduces transactivation activity; delays nuclear translocation; does not exert a dominant negative effect; impairs DNA binding
V → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R477HVAR_013472477in GCCR; dbSNP:rs104893913
R → H
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R477SVAR_077143477in GCCR; loss of DNA-binding and of transactivation activity; incomplete dexamethasone-induced translocation to the nucleus; no effect on dexamethasone-binding affinity compared with wild-type
R → S
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Y478CVAR_077144478in GCCR; decreased DNA-binding and transactivation activity; incomplete dexamethasone-induced translocation to the nucleus; no effect on dexamethasone-binding affinity compared with wild-type
Y → C
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
T556IVAR_075800556in GCCR; reduces transactivation activity; enhances transrepression activity; reduces affinity for ligand; delays nuclear translocation; does not exert a dominant negative effect; does not impair DNA binding
T → I
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
I559NVAR_015632559in GCCR; interferes with translocation to the nucleus and thereby strongly reduces transcription activation; is equally impaired in nuclear export; acts as dominant negative mutant; dbSNP:rs104893909
I → N
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
V571AVAR_025014571in pseudohermaphroditism; female with hypokalemia due to glucocorticoid resistance; 6-fold reduction in binding affinity compared with the wild-type receptor; dbSNP:rs104893911
V → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
V575GVAR_075801575in GCCR; uncertain significance; reduces transactivation activity; enhances transrepression activity; reduces affinity for ligand; delays nuclear translocation; does not exert a dominant negative effect; does not impair DNA binding
V → G
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
D641VVAR_004676641in GCCR; dbSNP:rs104893908
D → V
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
L672PVAR_077145672in GCCR; loss of dexamethasone-binding, dexamethasone-induced translocation to the nucleus and of transactivation activity
L → P
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
G679SVAR_013473679in GCCR; has 50% binding affinity; dbSNP:rs104893914
G → S
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R714QVAR_075802714in GCCR; uncertain significance; reduces transactivation; reduces affinity for ligand; exerts a dominant negative effect; does not impair DNA binding
R → Q
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
H726RVAR_075803726in GCCR; uncertain significance; reduces transactivation and transrepression activity; reduces affinity for ligand; delays nuclear translocation; does not impair DNA binding
H → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
V729IVAR_004677729in GCCR; dbSNP:rs1027058734
V → I
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
F737LVAR_071935737in GCCR; reduces transactivation of the glucocorticoid-inducible tumor virus promoter; reduces affinity for ligand; delays its nuclear translocation; acts as dominant negative mutant; dbSNP:rs121909727
F → L
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
I747MVAR_015633747in GCCR; alters interaction with NCOA2 and strongly reduces transcription activation; acts as a dominant negative mutant; dbSNP:rs104893910
I → M
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
L753FVAR_004678753in dbSNP:rs121909726
L → F
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
N766SVAR_075804766associated in cis with D-72 and A-321 in one individual; doubles transactivation potential
N → S
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
L773PVAR_071936773in GCCR; reduces transactivation of the glucocorticoid-inducible tumor virus promoter; reduces affinity for ligand; delays its nuclear translocation; acts as dominant negative mutant; dbSNP:rs104893912
L → P
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure

Laboratory mutagenesis 37

Scroll across the table for evidence and actions.

37 recorded rows

FeaturePositionDescriptionEvidenceInspect
M1T1Abolishes expression of A-type isoforms.
M → T
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
M27T27Abolishes expression of B-type isoforms.
M → T
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
M86I86Abolishes expression of C-type isoforms; when associated with I-90 and I-98.
M → I
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
M90I90Abolishes expression of C-type isoforms; when associated with I-86 and I-98.
M → I
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
M98I98Abolishes expression of C-type isoforms; when associated with I-86 and I-90.
M → I
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
D101A101Reduces transcription activation activity of isoform Alpha-C3 by half.
D → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
D101K101Reduces transcription activation activity of isoform Alpha-C3 by half. Suppresses apoptosis-inducing activity of isoform Alpha-C3. Impairs recruitment of selected coregulators onto DNA binding sites.
D → K
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
QQ106LL106–107Reduces activity of isoform Alpha-C3 by half.
QQ → LL
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
SS113AA113–114Does not affect the activity of isoform Alpha-C3.
SS → AA
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
F191D191Reduces transactivation by the ADA complex.
F → D
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
I193D193Reduces transactivation by the ADA complex.
I → D
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
L194A194Strongly reduces transactivation by the ADA complex; when associated with V-224 and F-225.
L → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
L197E197Reduces transactivation by the ADA complex.
L → E
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
S211A211Reduces expression of target genes IGFBP1 and IRF8.
S → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
W213A213Strongly reduces transactivation by the ADA complex.
W → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
L224V224Strongly reduces transactivation by the ADA complex; when associated with A-194 and F-225.
L → V
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
L225F225Strongly reduces transactivation by the ADA complex; when associated with A-194 and V-224.
L → F
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
S226A226Abolishes phosphorylation and enhances transcriptional activation.
S → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
F235L235Strongly reduces transactivation by the ADA complex; when associated with V-236.
F → L
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
L236V236Strongly reduces transactivation by the ADA complex; when associated with L-235.
L → V
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K277R277Strongly reduces sumoylation. Almost complete loss of sumoylation; when associated with R-293.
K → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K293R293Strongly reduces sumoylation. Almost complete loss of sumoylation; when associated with R-277.
K → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
M316I316Abolishes expression of D-type isoforms; when associated with I-331 and I-336.
M → I
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
M331I331Abolishes expression of D-type isoforms; when associated with I-316 and I-336.
M → I
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
M336I336Abolishes expression of D-type isoforms; when associated with I-316 and I-331.
M → I
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
S404A404Abolishes phosphorylation. Does not affect translocation to the nucleus following ligand stimulation. Increases protein half-life and transcriptional repressor activity. Alters repertoire of regulated genes. Increases cell death.
S → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
S404D404Does not affect translocation to the nucleus following ligand stimulation.
S → D
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K480A480Decrease in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer. Complete loss in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer; when associated with A-492; A-494 and A-495.
K → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K492A492Decrease in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer. Complete loss in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer; when associated with A-480; A-494 and A-495.
K → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K494A494Decrease in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer; when associated with A-495. Complete loss in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer; when associated with A-480; A-492 and A-495.
K → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K495A495Decrease in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer; when associated with A-494. Complete loss in acetylation and in repression of its transcriptional activity by CLOCK-BMAL1 heterodimer; when associated with A-480; A-492 and A-494.
K → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R585A585Reduces activation mediated by ligand binding domain; when associated with A-590.
R → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
D590A590Reduces activation mediated by ligand binding domain; when associated with A-585.
D → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
F602S602Increases solubility. No effect on transactivation by dexamethasone.
F → S
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
P625A625Decreases transactivation by dexamethasone by 95%.
P → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
I628A628Decreases dimerization and transactivation by dexamethasone; when associated with S-602.
I → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K703R703Slightly reduces sumoylation. Inhibits the stimulatory effect of RWDD3 on its transcriptional activity.
K → R
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
05

PTM/Processing

Acetylation by CLOCK reduces its binding to glucocorticoid response elements and its transcriptional activity

Experimental evidence 2 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "19141540"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "21980503"
        }
      ],
      "value": "Acetylation by CLOCK reduces its binding to glucocorticoid response elements and its transcriptional activity"
    }
  ],
  "commentType": "PTM"
}

Increased proteasome-mediated degradation in response to glucocorticoids [29]. Isoform Alpha-B appears to be more susceptible to proteolytic degradation than isoform Alpha [31]

Experimental evidence 2 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "11435610"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "11555652"
        }
      ],
      "value": "Increased proteasome-mediated degradation in response to glucocorticoids (PubMed:11555652). Isoform Alpha-B appears to be more susceptible to proteolytic degradation than isoform Alpha (PubMed:11435610)"
    }
  ],
  "commentType": "PTM"
}

Phosphorylated in the absence of hormone; becomes hyperphosphorylated in the presence of glucocorticoid. The Ser-203, Ser-226 and Ser-404-phosphorylated forms are mainly cytoplasmic, and the Ser-211-phosphorylated form is nuclear [34, 46]. Phosphorylation at Ser-211 increases transcriptional activity [34, 47].

Phosphorylation at Ser-203, Ser-226 and Ser-404 decreases signaling capacity [34, 47, 46]. Phosphorylation at Ser-404 may protect from glucocorticoid-induced apoptosis [46]. Phosphorylation at Ser-203 and Ser-211 is not required in regulation of chromosome segregation [69].

May be dephosphorylated by PPP5C, attenuates NR3C1 action (By similarity)

By similarityExperimental evidence 4 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000250",
          "source": "UniProtKB",
          "id": "P06537"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "12000743"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "18483179"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "18838540"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "25847991"
        }
      ],
      "value": "Phosphorylated in the absence of hormone; becomes hyperphosphorylated in the presence of glucocorticoid. The Ser-203, Ser-226 and Ser-404-phosphorylated forms are mainly cytoplasmic, and the Ser-211-phosphorylated form is nuclear (PubMed:12000743, PubMed:18838540). Phosphorylation at Ser-211 increases transcriptional activity (PubMed:12000743, PubMed:18483179). Phosphorylation at Ser-203, Ser-226 and Ser-404 decreases signaling capacity (PubMed:12000743, PubMed:18483179, PubMed:18838540). Phosphorylation at Ser-404 may protect from glucocorticoid-induced apoptosis (PubMed:18838540). Phosphorylation at Ser-203 and Ser-211 is not required in regulation of chromosome segregation (PubMed:25847991). May be dephosphorylated by PPP5C, attenuates NR3C1 action (By similarity)"
    }
  ],
  "commentType": "PTM"
}

Ubiquitinated by UBR5, leading to its degradation: UBR5 specifically recognizes and binds ligand-bound NR3C1 when it is not associated with coactivators (NCOAs) [74]. In presence of NCOAs, the UBR5-degron is not accessible, preventing its ubiquitination and degradation [74]

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "37478846"
        }
      ],
      "value": "Ubiquitinated by UBR5, leading to its degradation: UBR5 specifically recognizes and binds ligand-bound NR3C1 when it is not associated with coactivators (NCOAs) (PubMed:37478846). In presence of NCOAs, the UBR5-degron is not accessible, preventing its ubiquitination and degradation (PubMed:37478846)"
    }
  ],
  "commentType": "PTM"
}

Sumoylation at Lys-277 and Lys-293 negatively regulates its transcriptional activity [33]. Sumoylation at Lys-703 positively regulates its transcriptional activity in the presence of RWDD3 (By similarity). Sumoylation at Lys-277 and Lys-293 is dispensable whereas sumoylation at Lys-703 is critical for the stimulatory effect of RWDD3 on its transcriptional activity (By similarity).

Heat shock increases sumoylation in a RWDD3-dependent manner (By similarity)

By similarityExperimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000250",
          "source": "UniProtKB",
          "id": "P06536"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "12144530"
        }
      ],
      "value": "Sumoylation at Lys-277 and Lys-293 negatively regulates its transcriptional activity (PubMed:12144530). Sumoylation at Lys-703 positively regulates its transcriptional activity in the presence of RWDD3 (By similarity). Sumoylation at Lys-277 and Lys-293 is dispensable whereas sumoylation at Lys-703 is critical for the stimulatory effect of RWDD3 on its transcriptional activity (By similarity). Heat shock increases sumoylation in a RWDD3-dependent manner (By similarity)"
    }
  ],
  "commentType": "PTM"
}

Processed chains & precursor regions 1

Scroll across the table for evidence and actions.

1 recorded rows

FeaturePositionDescriptionEvidenceInspect
ChainPRO_00000199371–777Glucocorticoid receptor
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure

Modifications 24

Scroll across the table for evidence and actions.

24 recorded rows

FeaturePositionDescriptionEvidenceInspect
Modified residue8Phosphothreonine
1 publication
Evidence & references
No verified residues in this structure
Modified residue23Omega-N-methylarginine
By similarity
Evidence & references
  • ECO:0000250 UniProtKB:P06537
No verified residues in this structure
Modified residue45Phosphoserine
1 publication
Evidence & references
No verified residues in this structure
Modified residue113Phosphoserine
By similarity
Evidence & references
  • ECO:0000250 UniProtKB:P06537
No verified residues in this structure
Modified residue134Phosphoserine
1 publication
Evidence & references
No verified residues in this structure
Modified residue141Phosphoserine
By similarity
Evidence & references
  • ECO:0000250 UniProtKB:P06537
No verified residues in this structure
Modified residue203Phosphoserine
Experimental evidence 4 publications
Evidence & references
No verified residues in this structure
Modified residue211Phosphoserine
Experimental evidence 3 publications
Evidence & references
No verified residues in this structure
Modified residue226Phosphoserine
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
Modified residue267Phosphoserine
2 publications
Evidence & references
No verified residues in this structure
Modified residue404Phosphoserine; by GSK3-beta
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Modified residue480N6-acetyllysine
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Modified residue492N6-acetyllysine
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Modified residue494N6-acetyllysine
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Modified residue495N6-acetyllysine
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Cross-link258Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)
1 publication
Evidence & references
No verified residues in this structure
Cross-link277Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Cross-link277Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate
1 publication
Evidence & references
No verified residues in this structure
Cross-link293Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); alternate
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Cross-link293Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2); alternate
1 publication
Evidence & references
No verified residues in this structure
Cross-link419Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
By similarity
Evidence & references
  • ECO:0000250 UniProtKB:P06537
No verified residues in this structure
Cross-link703Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO)
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Modified residue1N-acetylmethionineP04150-8
1 publication
Evidence & references
No verified residues in this structure · isoform-specific coordinates
Modified residue1N-acetylmethionineP04150-9
1 publication
Evidence & references
No verified residues in this structure · isoform-specific coordinates
06

Expression

Widely expressed including bone, stomach, lung, liver, colon, breast, ovary, pancreas and kidney [69]. In the heart, detected in left and right atria, left and right ventricles, aorta, apex, intraventricular septum, and atrioventricular node as well as whole adult and fetal heart [25]

Experimental evidence 2 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "10902803"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "25847991"
        }
      ],
      "value": "Widely expressed including bone, stomach, lung, liver, colon, breast, ovary, pancreas and kidney (PubMed:25847991). In the heart, detected in left and right atria, left and right ventricles, aorta, apex, intraventricular septum, and atrioventricular node as well as whole adult and fetal heart (PubMed:10902803)"
    }
  ],
  "commentType": "TISSUE SPECIFICITY"
}
Isoform Beta

Widely expressed including brain, bone marrow, thymus, spleen, liver, kidney, pancreas, lung, fat, skeletal muscle, heart, placenta and blood leukocytes

Experimental evidence 2 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "7769088"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "8621628"
        }
      ],
      "value": "Widely expressed including brain, bone marrow, thymus, spleen, liver, kidney, pancreas, lung, fat, skeletal muscle, heart, placenta and blood leukocytes"
    }
  ],
  "commentType": "TISSUE SPECIFICITY",
  "molecule": "Isoform Beta"
}
Isoform Alpha-2

Widely expressed

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "10566686"
        }
      ],
      "value": "Widely expressed"
    }
  ],
  "commentType": "TISSUE SPECIFICITY",
  "molecule": "Isoform Alpha-2"
}

Induction

Isoform Alpha

Induced by TNF (at protein level)

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "11381138"
        }
      ],
      "value": "Induced by TNF (at protein level)"
    }
  ],
  "commentType": "INDUCTION",
  "molecule": "Isoform Alpha"
}
Isoform Beta

Induced by TNF and becomes the predominant isoform which may lead to glucocorticoid resistance (at protein level)

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "11381138"
        }
      ],
      "value": "Induced by TNF and becomes the predominant isoform which may lead to glucocorticoid resistance (at protein level)"
    }
  ],
  "commentType": "INDUCTION",
  "molecule": "Isoform Beta"
}
07

Interaction

Documented interaction partners

UniProt’s filtered IntAct records. Experiment counts describe reported experiments, not binding strength or independent publications. Separate products remain separate rows.

14 records
Partner / productSpeciesExperimentsEvidence & actions
AKT1P31749With P04150Homo sapiens5
IntAct evidence

Pair evidence in IntAct ↗

Source product: P04150. Partner: P31749. Reported experiment count: 5.

Open protein ↗
CD4P01730With P04150Homo sapiens2
IntAct evidence

Pair evidence in IntAct ↗

Source product: P04150. Partner: P01730. Reported experiment count: 2.

Open protein ↗
EGFRP00533With P04150Homo sapiens3
IntAct evidence

Pair evidence in IntAct ↗

Source product: P04150. Partner: P00533. Reported experiment count: 3.

Open protein ↗
HNF4AP41235With P04150Homo sapiens2
IntAct evidence

Pair evidence in IntAct ↗

Source product: P04150. Partner: P41235. Reported experiment count: 2.

Open protein ↗
HSP90AA1P07900With P04150Homo sapiens8
IntAct evidence

Pair evidence in IntAct ↗

Source product: P04150. Partner: P07900. Reported experiment count: 8.

Open protein ↗
KIAA0408Q6ZU52With P04150Homo sapiens2
IntAct evidence

Pair evidence in IntAct ↗

Source product: P04150. Partner: Q6ZU52. Reported experiment count: 2.

Open protein ↗
LCKP06239With P04150Homo sapiens3
IntAct evidence

Pair evidence in IntAct ↗

Source product: P04150. Partner: P06239. Reported experiment count: 3.

Open protein ↗
RXRBP28702With P04150Homo sapiens4
IntAct evidence

Pair evidence in IntAct ↗

Source product: P04150. Partner: P28702. Reported experiment count: 4.

Open protein ↗
SEPTIN6Q14141With P04150Homo sapiens3
IntAct evidence

Pair evidence in IntAct ↗

Source product: P04150. Partner: Q14141. Reported experiment count: 3.

Open protein ↗
SOX14O95416With P04150Homo sapiens3
IntAct evidence

Pair evidence in IntAct ↗

Source product: P04150. Partner: O95416. Reported experiment count: 3.

Open protein ↗
TMF1P82094With P04150Homo sapiens3
IntAct evidence

Pair evidence in IntAct ↗

Source product: P04150. Partner: P82094. Reported experiment count: 3.

Open protein ↗
Asxl1P59598With P04150Mus musculusCross-species2
IntAct evidence

Pair evidence in IntAct ↗

Source product: P04150. Partner: P59598. Reported experiment count: 2.

Open protein ↗
MvpQ62667With P04150Rattus norvegicusCross-species2
IntAct evidence

Pair evidence in IntAct ↗

Source product: P04150. Partner: Q62667. Reported experiment count: 2.

Open protein ↗
Ncoa2Q61026With P04150-1Mus musculusCross-species3
IntAct evidence

Pair evidence in IntAct ↗

Source product: P04150-1. Partner: Q61026. Reported experiment count: 3.

Open protein ↗

Complex membership & assembly descriptions

Co-membership does not by itself prove direct binding between every pair.

No Complex Portal cross-reference was recorded for this entry.

UniProt subunit description

Heteromultimeric cytoplasmic complex with HSP90AA1, HSPA1A/HSPA1B, and FKBP5 or another immunophilin such as PPID, STIP1, or the immunophilin homolog PPP5C [57]. Upon ligand binding FKBP5 dissociates from the complex and FKBP4 takes its place, thereby linking the complex to dynein and mediating transport to the nucleus, where the complex dissociates (By similarity). Probably forms a complex composed of chaperones HSP90 and HSP70, co-chaperones CDC37, PPP5C, TSC1 and client protein TSC2, CDK4, AKT, RAF1 and NR3C1; this complex does not contain co-chaperones STIP1/HOP and PTGES3/p23 [71].

Directly interacts with UNC45A [43]. Binds to DNA as a homodimer, and as heterodimer with NR3C2 or the retinoid X receptor. Binds STAT5A and STAT5B homodimers and heterodimers (By similarity).

Interacts with NRIP1, POU2F1, POU2F2 and TRIM28 (By similarity). Interacts with several coactivator complexes, including the SMARCA4 complex, CREBBP/EP300, TADA2L (Ada complex) and p160 coactivators such as NCOA2 and NCOA6 [26, 75, 76, 21, 22]. Interaction with BAG1 inhibits transactivation [23].

Interacts with HEXIM1 and TGFB1I1 [35, 38, 41]. Interacts with NCOA1 [22]. Interacts with NCOA3, SMARCA4, SMARCC1, SMARCD1, and SMARCE1 (By similarity).

Interacts with CLOCK, CRY1 and CRY2 in a ligand-dependent fashion [50, 59, 58]. Interacts with CIART (By similarity). Interacts with RWDD3 (By similarity).

Interacts with UBE2I/UBC9 and this interaction is enhanced in the presence of RWDD3 (By similarity). Interacts with GRIP1 [94, 96]. Interacts with NR4A3 (via nuclear receptor DNA-binding domain), represses transcription activity of NR4A3 on the POMC promoter Nur response element (NurRE) [40].

Directly interacts with PNRC2 to attract and form a complex with UPF1 and DCP1A; the interaction leads to rapid mRNA degradation [68]. Interacts with GSK3B [46]. Interacts with FNIP1 and FNIP2 [70].

Interacts (via C-terminus) with HNRNPU (via C-terminus) [20]. Interacts with MCM3AP [42]. Interacts (via domain NR LBD) with HSP90AA1 and HSP90AB1 (By similarity).

In the absence of hormonal ligand, interacts with TACC1 [52]. Interacts (via NR LBD domain) with ZNF764 (via KRAB domain); the interaction regulates transcription factor activity of NR3C1 by directing its actions toward certain biologic pathways [73]

By similarityExperimental evidence 24 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000250",
          "source": "UniProtKB",
          "id": "P06536"
        },
        {
          "evidenceCode": "ECO:0000250",
          "source": "UniProtKB",
          "id": "P06537"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "10477749"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "10866662"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "12151000"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "12686538"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15211577"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15591535"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15769988"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15941832"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "16478993"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "16914116"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17635946"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "18838540"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "19141540"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "20078863"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "21730050"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "21980503"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "22170608"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "25775514"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "27353360"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "28139699"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "29127155"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "9154805"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "9353307"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "9590696"
        }
      ],
      "value": "Heteromultimeric cytoplasmic complex with HSP90AA1, HSPA1A/HSPA1B, and FKBP5 or another immunophilin such as PPID, STIP1, or the immunophilin homolog PPP5C (PubMed:21730050). Upon ligand binding FKBP5 dissociates from the complex and FKBP4 takes its place, thereby linking the complex to dynein and mediating transport to the nucleus, where the complex dissociates (By similarity). Probably forms a complex composed of chaperones HSP90 and HSP70, co-chaperones CDC37, PPP5C, TSC1 and client protein TSC2, CDK4, AKT, RAF1 and NR3C1; this complex does not contain co-chaperones STIP1/HOP and PTGES3/p23 (PubMed:29127155). Directly interacts with UNC45A (PubMed:16478993). Binds to DNA as a homodimer, and as heterodimer with NR3C2 or the retinoid X receptor. Binds STAT5A and STAT5B homodimers and heterodimers (By similarity). Interacts with NRIP1, POU2F1, POU2F2 and TRIM28 (By similarity). Interacts with several coactivator complexes, including the SMARCA4 complex, CREBBP/EP300, TADA2L (Ada complex) and p160 coactivators such as NCOA2 and NCOA6 (PubMed:10866662, PubMed:12151000, PubMed:12686538, PubMed:9154805, PubMed:9590696). Interaction with BAG1 inhibits transactivation (PubMed:10477749). Interacts with HEXIM1 and TGFB1I1 (PubMed:12415108, PubMed:15211577, PubMed:15941832). Interacts with NCOA1 (PubMed:9590696). Interacts with NCOA3, SMARCA4, SMARCC1, SMARCD1, and SMARCE1 (By similarity). Interacts with CLOCK, CRY1 and CRY2 in a ligand-dependent fashion (PubMed:19141540, PubMed:21980503, PubMed:22170608). Interacts with CIART (By similarity). Interacts with RWDD3 (By similarity). Interacts with UBE2I/UBC9 and this interaction is enhanced in the presence of RWDD3 (By similarity). Interacts with GRIP1 (PubMed:15769988, PubMed:17635946). Interacts with NR4A3 (via nuclear receptor DNA-binding domain), represses transcription activity of NR4A3 on the POMC promoter Nur response element (NurRE) (PubMed:15591535). Directly interacts with PNRC2 to attract and form a complex with UPF1 and DCP1A; the interaction leads to rapid mRNA degradation (PubMed:25775514). Interacts with GSK3B (PubMed:18838540). Interacts with FNIP1 and FNIP2 (PubMed:27353360). Interacts (via C-terminus) with HNRNPU (via C-terminus) (PubMed:9353307). Interacts with MCM3AP (PubMed:16914116). Interacts (via domain NR LBD) with HSP90AA1 and HSP90AB1 (By similarity). In the absence of hormonal ligand, interacts with TACC1 (PubMed:20078863). Interacts (via NR LBD domain) with ZNF764 (via KRAB domain); the interaction regulates transcription factor activity of NR3C1 by directing its actions toward certain biologic pathways (PubMed:28139699)"
    }
  ],
  "commentType": "SUBUNIT"
}

Other association resources

Resource links only; their association networks and counts are not added to the partner table.

08

Structure

7KW7 · Atomic cryoEM structure of Hsp90-Hsp70-Hop-GR

ELECTRON MICROSCOPY · 3.57 Å

Recorded components

ComponentSpeciesChainsProtein identities
Heat shock protein HSP 90-alphaprotein · Entity 1Homo sapiensA, BP07900
Heat shock 70 kDa protein 1Aprotein · Entity 2Homo sapiensC, DP0DMV8
Stress-induced-phosphoprotein 1protein · Entity 3Homo sapiensEP31948
Glucocorticoid receptorprotein · Entity 4Homo sapiensFP04150
ADENOSINE-5'-DIPHOSPHATEligand · Entity 5G, JNo verified protein mapping
MAGNESIUM IONligand · Entity 6H, KNo verified protein mapping
POTASSIUM IONligand · Entity 7I, LNo verified protein mapping

Biological assemblies

Assembly 1 · author_defined_assembly
Recorded chains: A, B, C, D, E, F, G, H, I, J, K, L

Assembly membership does not establish direct binding. Observed residue coverage is checked against the loaded coordinates; it is not inferred from construct metadata.

Publication

Structure of Hsp90-Hsp70-Hop-GR reveals the Hsp90 client-loading mechanism.

22/12/2021 · Read publication ↗

Detailed validation, construct lengths and deposition dates are not included in this published record. See the source record for those details.

PDB source record ↗

Structure references are from the dated source record. Opening another structure follows your existing Atlas account permissions.

Available structures 59

Scroll across the table for evidence and actions.

59 recorded rows

RecordEvidence typeMethodResolutionOpen
7KW7experimentalEM3.57 AOpen in Atlas ↗
7PRWexperimentalX-ray2.50 AOpen in Atlas ↗
7PRVexperimentalX-ray2.70 AOpen in Atlas ↗
8FFVexperimentalEM3.01 AOpen in Atlas ↗
8FFWexperimentalEM3.23 AOpen in Atlas ↗
4UDDexperimentalX-ray1.80 AOpen in Atlas ↗
5NFPexperimentalX-ray2.10 AOpen in Atlas ↗
6EL7experimentalX-ray2.18 AOpen in Atlas ↗
6EL9experimentalX-ray2.19 AOpen in Atlas ↗
5G5WexperimentalX-ray2.20 AOpen in Atlas ↗
1NHZexperimentalX-ray2.30 AOpen in Atlas ↗
4CSJexperimentalX-ray2.30 AOpen in Atlas ↗
5NFTexperimentalX-ray2.30 AOpen in Atlas ↗
5G3JexperimentalX-ray2.40 AOpen in Atlas ↗
6EL6experimentalX-ray2.40 AOpen in Atlas ↗
5UC3experimentalX-ray2.01 AOpen in Atlas ↗
4P6WexperimentalX-ray1.95 AOpen in Atlas ↗
4UDCexperimentalX-ray2.50 AOpen in Atlas ↗
3K22experimentalX-ray2.10 AOpen in Atlas ↗
3E7CexperimentalX-ray2.15 AOpen in Atlas ↗
1P93experimentalX-ray2.70 AOpen in Atlas ↗
8VKZexperimentalX-ray2.13 AOpen in Atlas ↗
7PRXexperimentalX-ray2.20 AOpen in Atlas ↗
4LSJexperimentalX-ray2.35 AOpen in Atlas ↗
4MDDexperimentalX-ray2.40 AOpen in Atlas ↗
1M2ZexperimentalX-ray2.50 AOpen in Atlas ↗
7KRJexperimentalEM2.56 AOpen in Atlas ↗
4P6XexperimentalX-ray2.50 AOpen in Atlas ↗
3BQDexperimentalX-ray2.50 AOpen in Atlas ↗
3CLDexperimentalX-ray2.84 AOpen in Atlas ↗
3H52experimentalX-ray2.80 AOpen in Atlas ↗
3K23experimentalX-ray3.00 AOpen in Atlas ↗
6DXKexperimentalX-ray3.05 AOpen in Atlas ↗
5E69experimentalX-ray1.85 AOpen in Atlas ↗
4HN5experimentalX-ray1.90 AOpen in Atlas ↗
5CBXexperimentalX-ray2.00 AOpen in Atlas ↗
5CBYexperimentalX-ray2.00 AOpen in Atlas ↗
5E6AexperimentalX-ray2.20 AOpen in Atlas ↗
5E6CexperimentalX-ray2.20 AOpen in Atlas ↗
5E6BexperimentalX-ray2.25 AOpen in Atlas ↗
5CC1experimentalX-ray2.30 AOpen in Atlas ↗
5EMCexperimentalX-ray2.30 AOpen in Atlas ↗
5EMPexperimentalX-ray2.30 AOpen in Atlas ↗
5EMQexperimentalX-ray2.30 AOpen in Atlas ↗
6X6EexperimentalX-ray2.00 AOpen in Atlas ↗
5CBZexperimentalX-ray2.20 AOpen in Atlas ↗
5E6DexperimentalX-ray2.40 AOpen in Atlas ↗
6CFNexperimentalX-ray2.50 AOpen in Atlas ↗
4HN6experimentalX-ray2.55 AOpen in Atlas ↗
5VA7experimentalX-ray2.15 AOpen in Atlas ↗
5VA0experimentalX-ray2.29 AOpen in Atlas ↗
6X6DexperimentalX-ray2.48 AOpen in Atlas ↗
6BQUexperimentalX-ray2.50 AOpen in Atlas ↗
8A9GexperimentalX-ray1.96 AOpen in Atlas ↗
6YMOexperimentalX-ray2.02 AOpen in Atlas ↗
5UC1experimentalX-ray2.35 AOpen in Atlas ↗
6YO8experimentalX-ray2.09 AOpen in Atlas ↗
6YOSexperimentalX-ray2.75 AOpen in Atlas ↗
AF-P04150-F1predictedAlphaFoldNot applicableOpen in Atlas ↗
09

Family & Domains

Composed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain [16]. The ligand-binding domain is required for correct chromosome segregation during mitosis although ligand binding is not required [69]

Experimental evidence 2 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "25847991"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "3841189"
        }
      ],
      "value": "Composed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain (PubMed:3841189). The ligand-binding domain is required for correct chromosome segregation during mitosis although ligand binding is not required (PubMed:25847991)"
    }
  ],
  "commentType": "DOMAIN"
}

Belongs to the nuclear hormone receptor family. NR3 subfamily

Curator inference
Evidence & references
  • ECO:0000305
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000305"
        }
      ],
      "value": "Belongs to the nuclear hormone receptor family. NR3 subfamily"
    }
  ],
  "commentType": "SIMILARITY"
}

Domain architecture

Canonical sequence1777 aa

Canonical coordinates. Overlapping marks share a lane; individual records and evidence are in the tables below. Gaps in coverage are not selectable in 3D. Use the track links and tables for keyboard inspection.

Atlas domains, motifs & repeats 2

Scroll across the table for evidence and actions.

2 recorded rows

AnnotationPositionSource & interpretationInspect
Zinc finger, nuclear hormone receptor-typeIPR001628418–493INTERPROdomain

This entry represents the two C4-type zinc finger modules involved in DNA-binding. Steroid or nuclear hormone receptors constitute an important superfamily of transcription regulators that are involved in widely diverse physiological functions, including control of embryonic development, cell differentiation and homeostasis.

Full source description

This entry represents the two C4-type zinc finger modules involved in DNA-binding. Steroid or nuclear hormone receptors constitute an important superfamily of transcription regulators that are involved in widely diverse physiological functions, including control of embryonic development, cell differentiation and homeostasis. The receptors function as dimeric molecules in nuclei to regulate the transcription of target genes in a ligand-responsive manner. Nuclear hormone receptors consist of a highly conserved DNA-binding domain that recognises specific sequences, connected via a linker region to a C-terminal ligand-binding domain ([interpro:IPR000536]). In addition, certain nuclear hormone receptors have an N-terminal modulatory domain ([interpro:IPR001292]). The DNA-binding domain can elicit either an activating or repressing effect by binding to specific regions of the DNA known as hormone-response elements. These response elements position the receptors, and the complexes recruited by them, close to the genes of which transcription is affected. The DNA-binding domains of nuclear receptors consist of two zinc-nucleated modules and a C-terminal extension, where residues in the first zinc module determine the specificity of the DNA recognition and residues in the second zinc module are involved in dimerisation. The DNA-binding domain is furthermore involved in several other functions including nuclear localisation, and interaction with transcription factors and co-activators. Zinc finger (Znf) domains are relatively small protein motifs which contain multiple finger-like protrusions that make tandem contacts with their target molecule. Some of these domains bind zinc, but many do not; instead, they bind other metals, such as iron, or no metal at all. For example, some family members form salt bridges to stabilise the finger-like folds. They were first identified as a DNA-binding motif in transcription factor TFIIIA from Xenopus laevis (African clawed frog); however, they are now recognised to bind DNA, RNA, protein and/or lipid substrates. Their binding properties depend on the amino acid sequence of the finger domains and of the linker between fingers, as well as on the higher-order structures and the number of fingers. Znf domains are often found in clusters, where fingers can have different binding specificities. There are many superfamilies of Znf motifs, varying in both sequence and structure. They display considerable versatility in binding modes, even between members of the same class (e.g., some bind DNA, others protein), suggesting that Znf motifs are stable scaffolds that have evolved specialised functions. For example, Znf-containing proteins function in gene transcription, translation, mRNA trafficking, cytoskeleton organisation, epithelial development, cell adhesion, protein folding, chromatin remodelling and zinc sensing, to name but a few. Zinc-binding motifs are stable structures, and they rarely undergo conformational changes upon binding their target.

Source entry ↗
No verified residues in this structure
Nuclear hormone receptor, ligand-binding domainIPR000536524–758INTERPROdomain

Nuclear receptors (NRs), such as the receptors for steroids and thyroid hormones, retinoids and vitamin D3, are one of the most abundant classes of transcriptional regulators in animals (metazoans). They regulate diverse functions, such as homeostasis, reproduction, development and metabolism.

Full source description

Nuclear receptors (NRs), such as the receptors for steroids and thyroid hormones, retinoids and vitamin D3, are one of the most abundant classes of transcriptional regulators in animals (metazoans). They regulate diverse functions, such as homeostasis, reproduction, development and metabolism. The most prominent feature differentiating them from other transcription factors is their capacity to bind small hydrophobic molecules specifically. These ligands constitute regulatory signals, which modify the NR transcriptional activity through conformational changes. Prototypical NRs share a common structural organisation with a variable N-terminal domain that contains a constitutively active activation function (AF)-1, a conserved DNA- binding domain (DBD) consisting of two zinc fingers, a linker region, and a C-terminal ligand-binding domain (LBD), also called HOLI domain. The NR LBD plays a crucial role in ligand-mediated NR activity. In addition to its role is ligand recognition, the LBD also contains a ligand-dependent AF-2. Conformational changes in AF-2 induced by various ligands can modulate interactions with conserved motifs of coregulatory proteins. Specifically, the binding of ligands to the LBD determines the recruiting of transcriptional coregulators which triggers induction or repression of target genes. The coregulators include coactivators like the p160 factors also referred to as the steroid receptor coactivators (SRC) family, and corepressors such as SMART (silencing mediator for retinoid and thyroid hormone receptors) and N-CoR (nuclear corepressor). The overall structure of NR LBD is composed of about 11-13 α-helices that are arranged into a three-layer antiparallel α-helical sandwich with the three long helices (helices 3, 7, and 10) forming the two outer layers. The middle layer of helices (helices 4, 5, 8 and 9) is present only in the top half of the domain but is missing from the bottom half, thereby creating a cavity, so called ligand-binding pocket, for ligand binding in most receptors. The bound ligands stabilize the NR conformation through direct contacts with multiple structural elements including helices H3, H5, H6, H7, H10, and the loop proceeding the AF-2 helix. The C-terminal activation region also forms an α-helix (AF-2), which can adopt multiple conformation depending on the nature of the bound ligand. Helices 3,4 and 12 enclose a shallow hydrophobic groove which is the site for coregulator binding. Despite the conserved fold of NR LBDs, the ligand-binding pocket is the least conserved region among different NR LBDs.

Source entry ↗
No verified residues in this structure

UniProt domains, repeats & motifs 1

Scroll across the table for evidence and actions.

1 recorded rows

FeaturePositionDescriptionEvidenceInspect
Domain524–758NR LBD
Sequence analysis
Evidence & references
  • ECO:0000255 PROSITE-ProRule:PRU01189
No verified residues in this structure

Functional sites 3

Scroll across the table for evidence and actions.

3 recorded rows

FeaturePositionDescriptionEvidenceInspect
DNA binding418–493Nuclear receptor
Sequence analysis
Evidence & references
  • ECO:0000255 PROSITE-ProRule:PRU00407
No verified residues in this structure
Zinc finger421–441NR C4-type
Sequence analysis
Evidence & references
  • ECO:0000255 PROSITE-ProRule:PRU00407
No verified residues in this structure
Zinc finger457–476NR C4-type
Sequence analysis
Evidence & references
  • ECO:0000255 PROSITE-ProRule:PRU00407
No verified residues in this structure

Sequence regions 14

Scroll across the table for evidence and actions.

14 recorded rows

FeaturePositionDescriptionEvidenceInspect
Region1–420Modulating
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
Region1–23Disordered
Evidence & references
  • ECO:0000256 SAM:MobiDB-lite
No verified residues in this structure
Region98–115Required for high transcriptional activity of isoform Alpha-C3
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Region130–183Disordered
Evidence & references
  • ECO:0000256 SAM:MobiDB-lite
No verified residues in this structure
Region394–415Disordered
Evidence & references
  • ECO:0000256 SAM:MobiDB-lite
No verified residues in this structure
Region485–777Interaction with CLOCK
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
Region487–523Hinge
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
Region532–697Interaction with CRY1
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Compositional bias1–14Basic and acidic residues
Evidence & references
  • ECO:0000256 SAM:MobiDB-lite
No verified residues in this structure
Compositional bias130–140Polar residues
Evidence & references
  • ECO:0000256 SAM:MobiDB-lite
No verified residues in this structure
Compositional bias141–150Low complexity
Evidence & references
  • ECO:0000256 SAM:MobiDB-lite
No verified residues in this structure
Compositional bias152–163Basic and acidic residues
Evidence & references
  • ECO:0000256 SAM:MobiDB-lite
No verified residues in this structure
Compositional bias164–174Polar residues
Evidence & references
  • ECO:0000256 SAM:MobiDB-lite
No verified residues in this structure
Compositional bias394–414Low complexity
Evidence & references
  • ECO:0000256 SAM:MobiDB-lite
No verified residues in this structure
10

Sequence & Isoforms

Sequence & isoforms

UniProt’s canonical sequence is its selected representative. It is not necessarily the dominant isoform in every tissue.

UniProt’s canonical sequence · P04150-1777 aa85,659 Da · source sequence mass

The mass describes this unmodified source sequence, not every mature or modified product.

MDSKESLTPGREENPSSVLAQERGDVMDFYKTLRGGATVKVSASSPSLAVASQSDSKQRRLLVDFPKGSVSNAQQPDLSKAVSLSMGLYMGETETKVMGNDLGFPQQGQISLSSGETDLKLLEESIANLNRSTSVPENPKSSASTAVSAAPTEKEFPKTHSDVSSEQQHLKGQTGTNGGNVKLYTTDQSTFDILQDLEFSSGSPGKETNESPWRSDLLIDENCLLSPLAGEDDSFLLEGNSNEDCKPLILPDTKPKIKDNGDLVLSSPSNVTLPQVKTEKEDFIELCTPGVIKQEKLGTVYCQASFPGANIIGNKMSAISVHGVSTSGGQMYHYDMNTASLSQQQDQKPIFNVIPPIPVGSENWNRCQGSGDDNLTSLGTLNFPGRTVFSNGYSSPSMRPDVSSPPSSSSTATTGPPPKLCLVCSDEASGCHYGVLTCGSCKVFFKRAVEGQHNYLCAGRNDCIIDKIRRKNCPACRYRKCLQAGMNLEARKTKKKIKGIQQATTGVSQETSENPGNKTIVPATLPQLTPTLVSLLEVIEPEVLYAGYDSSVPDSTWRIMTTLNMLGGRQVIAAVKWAKAIPGFRNLHLDDQMTLLQYSWMFLMAFALGWRSYRQSSANLLCFAPDLIINEQRMTLPCMYDQCKHMLYVSSELHRLQVSYEEYLCMKTLLLLSSVPKDGLKSQELFDEIRMTYIKELGKAIVKREGNSSQNWQRFYQLTKLLDSMHEVVENLLNYCFQTFLDKTMSIEFPEMLAEIITNQIPKYSNGNIKKLLFHQK

Source isoform notes & selection

Alternative splicing · Alternative initiation

Complete source annotation
{
  "commentType": "ALTERNATIVE PRODUCTS",
  "events": [
    "Alternative splicing",
    "Alternative initiation"
  ],
  "isoforms": [
    {
      "name": {
        "value": "Alpha"
      },
      "synonyms": [
        {
          "value": "Alpha-A"
        },
        {
          "value": "GR-alphaA"
        }
      ],
      "isoformIds": [
        "P04150-1"
      ],
      "isoformSequenceStatus": "Displayed"
    },
    {
      "name": {
        "value": "Beta"
      },
      "synonyms": [
        {
          "value": "Beta-A"
        }
      ],
      "isoformIds": [
        "P04150-2"
      ],
      "sequenceIds": [
        "VSP_003703"
      ],
      "isoformSequenceStatus": "Described"
    },
    {
      "name": {
        "value": "Alpha-2"
      },
      "synonyms": [
        {
          "value": "Gamma"
        }
      ],
      "isoformIds": [
        "P04150-3"
      ],
      "sequenceIds": [
        "VSP_007363"
      ],
      "isoformSequenceStatus": "Described"
    },
    {
      "name": {
        "value": "Beta-2"
      },
      "isoformIds": [
        "P04150-6"
      ],
      "sequenceIds": [
        "VSP_007363",
        "VSP_003703"
      ],
      "isoformSequenceStatus": "Described"
    },
    {
      "name": {
        "value": "GR-A alpha"
      },
      "isoformIds": [
        "P04150-5"
      ],
      "sequenceIds": [
        "VSP_013340"
      ],
      "isoformSequenceStatus": "Described"
    },
    {
      "name": {
        "value": "GR-A beta"
      },
      "isoformIds": [
        "P04150-7"
      ],
      "sequenceIds": [
        "VSP_013340",
        "VSP_003703"
      ],
      "isoformSequenceStatus": "Described"
    },
    {
      "name": {
        "value": "GR-P"
      },
      "isoformIds": [
        "P04150-4"
      ],
      "isoformSequenceStatus": "Not described"
    },
    {
      "name": {
        "value": "Alpha-B"
      },
      "synonyms": [
        {
          "value": "GR-alphaB"
        }
      ],
      "isoformIds": [
        "P04150-8"
      ],
      "sequenceIds": [
        "VSP_018773"
      ],
      "isoformSequenceStatus": "Described"
    },
    {
      "name": {
        "value": "Beta-B"
      },
      "isoformIds": [
        "P04150-9"
      ],
      "sequenceIds": [
        "VSP_018773",
        "VSP_003703"
      ],
      "isoformSequenceStatus": "Described"
    },
    {
      "name": {
        "value": "10"
      },
      "synonyms": [
        {
          "value": "hGRDelta313-338"
        }
      ],
      "isoformIds": [
        "P04150-10"
      ],
      "sequenceIds": [
        "VSP_043908"
      ],
      "isoformSequenceStatus": "Described"
    },
    {
      "name": {
        "value": "Alpha-C1"
      },
      "synonyms": [
        {
          "value": "GR-alphaC1"
        }
      ],
      "isoformIds": [
        "P04150-11"
      ],
      "sequenceIds": [
        "VSP_058317"
      ],
      "isoformSequenceStatus": "Described"
    },
    {
      "name": {
        "value": "Alpha-C2"
      },
      "synonyms": [
        {
          "value": "GR-alphaC2"
        }
      ],
      "isoformIds": [
        "P04150-12"
      ],
      "sequenceIds": [
        "VSP_058316"
      ],
      "isoformSequenceStatus": "Described"
    },
    {
      "name": {
        "value": "Alpha-C3"
      },
      "synonyms": [
        {
          "value": "GR-alphaC3"
        }
      ],
      "isoformIds": [
        "P04150-13"
      ],
      "sequenceIds": [
        "VSP_058315"
      ],
      "isoformSequenceStatus": "Described"
    },
    {
      "name": {
        "value": "Alpha-D1"
      },
      "synonyms": [
        {
          "value": "GR-alphaD1"
        }
      ],
      "isoformIds": [
        "P04150-14"
      ],
      "sequenceIds": [
        "VSP_058314"
      ],
      "isoformSequenceStatus": "Described"
    },
    {
      "name": {
        "value": "Alpha-D2"
      },
      "synonyms": [
        {
          "value": "GR-alphaD2"
        }
      ],
      "isoformIds": [
        "P04150-15"
      ],
      "sequenceIds": [
        "VSP_058313"
      ],
      "isoformSequenceStatus": "Described"
    },
    {
      "name": {
        "value": "Alpha-D3"
      },
      "synonyms": [
        {
          "value": "GR-alphaD3"
        }
      ],
      "isoformIds": [
        "P04150-16"
      ],
      "sequenceIds": [
        "VSP_058312"
      ],
      "isoformSequenceStatus": "Described"
    }
  ]
}
  • P04150-1 · Alpha · Displayed · Alpha-A, GR-alphaA
    Complete source annotation
    {
      "name": {
        "value": "Alpha"
      },
      "synonyms": [
        {
          "value": "Alpha-A"
        },
        {
          "value": "GR-alphaA"
        }
      ],
      "isoformIds": [
        "P04150-1"
      ],
      "isoformSequenceStatus": "Displayed"
    }
  • P04150-2 · Beta · Described · Beta-A · VSP_003703
    Complete source annotation
    {
      "name": {
        "value": "Beta"
      },
      "synonyms": [
        {
          "value": "Beta-A"
        }
      ],
      "isoformIds": [
        "P04150-2"
      ],
      "sequenceIds": [
        "VSP_003703"
      ],
      "isoformSequenceStatus": "Described"
    }
  • P04150-3 · Alpha-2 · Described · Gamma · VSP_007363
    Complete source annotation
    {
      "name": {
        "value": "Alpha-2"
      },
      "synonyms": [
        {
          "value": "Gamma"
        }
      ],
      "isoformIds": [
        "P04150-3"
      ],
      "sequenceIds": [
        "VSP_007363"
      ],
      "isoformSequenceStatus": "Described"
    }
  • P04150-6 · Beta-2 · Described · VSP_007363, VSP_003703
    Complete source annotation
    {
      "name": {
        "value": "Beta-2"
      },
      "isoformIds": [
        "P04150-6"
      ],
      "sequenceIds": [
        "VSP_007363",
        "VSP_003703"
      ],
      "isoformSequenceStatus": "Described"
    }
  • P04150-5 · GR-A alpha · Described · VSP_013340
    Complete source annotation
    {
      "name": {
        "value": "GR-A alpha"
      },
      "isoformIds": [
        "P04150-5"
      ],
      "sequenceIds": [
        "VSP_013340"
      ],
      "isoformSequenceStatus": "Described"
    }
  • P04150-7 · GR-A beta · Described · VSP_013340, VSP_003703
    Complete source annotation
    {
      "name": {
        "value": "GR-A beta"
      },
      "isoformIds": [
        "P04150-7"
      ],
      "sequenceIds": [
        "VSP_013340",
        "VSP_003703"
      ],
      "isoformSequenceStatus": "Described"
    }
  • P04150-4 · GR-P · Not described
    Complete source annotation
    {
      "name": {
        "value": "GR-P"
      },
      "isoformIds": [
        "P04150-4"
      ],
      "isoformSequenceStatus": "Not described"
    }
  • P04150-8 · Alpha-B · Described · GR-alphaB · VSP_018773
    Complete source annotation
    {
      "name": {
        "value": "Alpha-B"
      },
      "synonyms": [
        {
          "value": "GR-alphaB"
        }
      ],
      "isoformIds": [
        "P04150-8"
      ],
      "sequenceIds": [
        "VSP_018773"
      ],
      "isoformSequenceStatus": "Described"
    }
  • P04150-9 · Beta-B · Described · VSP_018773, VSP_003703
    Complete source annotation
    {
      "name": {
        "value": "Beta-B"
      },
      "isoformIds": [
        "P04150-9"
      ],
      "sequenceIds": [
        "VSP_018773",
        "VSP_003703"
      ],
      "isoformSequenceStatus": "Described"
    }
  • P04150-10 · 10 · Described · hGRDelta313-338 · VSP_043908
    Complete source annotation
    {
      "name": {
        "value": "10"
      },
      "synonyms": [
        {
          "value": "hGRDelta313-338"
        }
      ],
      "isoformIds": [
        "P04150-10"
      ],
      "sequenceIds": [
        "VSP_043908"
      ],
      "isoformSequenceStatus": "Described"
    }
  • P04150-11 · Alpha-C1 · Described · GR-alphaC1 · VSP_058317
    Complete source annotation
    {
      "name": {
        "value": "Alpha-C1"
      },
      "synonyms": [
        {
          "value": "GR-alphaC1"
        }
      ],
      "isoformIds": [
        "P04150-11"
      ],
      "sequenceIds": [
        "VSP_058317"
      ],
      "isoformSequenceStatus": "Described"
    }
  • P04150-12 · Alpha-C2 · Described · GR-alphaC2 · VSP_058316
    Complete source annotation
    {
      "name": {
        "value": "Alpha-C2"
      },
      "synonyms": [
        {
          "value": "GR-alphaC2"
        }
      ],
      "isoformIds": [
        "P04150-12"
      ],
      "sequenceIds": [
        "VSP_058316"
      ],
      "isoformSequenceStatus": "Described"
    }
  • P04150-13 · Alpha-C3 · Described · GR-alphaC3 · VSP_058315
    Complete source annotation
    {
      "name": {
        "value": "Alpha-C3"
      },
      "synonyms": [
        {
          "value": "GR-alphaC3"
        }
      ],
      "isoformIds": [
        "P04150-13"
      ],
      "sequenceIds": [
        "VSP_058315"
      ],
      "isoformSequenceStatus": "Described"
    }
  • P04150-14 · Alpha-D1 · Described · GR-alphaD1 · VSP_058314
    Complete source annotation
    {
      "name": {
        "value": "Alpha-D1"
      },
      "synonyms": [
        {
          "value": "GR-alphaD1"
        }
      ],
      "isoformIds": [
        "P04150-14"
      ],
      "sequenceIds": [
        "VSP_058314"
      ],
      "isoformSequenceStatus": "Described"
    }
  • P04150-15 · Alpha-D2 · Described · GR-alphaD2 · VSP_058313
    Complete source annotation
    {
      "name": {
        "value": "Alpha-D2"
      },
      "synonyms": [
        {
          "value": "GR-alphaD2"
        }
      ],
      "isoformIds": [
        "P04150-15"
      ],
      "sequenceIds": [
        "VSP_058313"
      ],
      "isoformSequenceStatus": "Described"
    }
  • P04150-16 · Alpha-D3 · Described · GR-alphaD3 · VSP_058312
    Complete source annotation
    {
      "name": {
        "value": "Alpha-D3"
      },
      "synonyms": [
        {
          "value": "GR-alphaD3"
        }
      ],
      "isoformIds": [
        "P04150-16"
      ],
      "sequenceIds": [
        "VSP_058312"
      ],
      "isoformSequenceStatus": "Described"
    }

Isoform sequence differences 11

Scroll across the table for evidence and actions.

11 recorded rows

FeaturePositionDescriptionEvidenceInspect
Alternative sequenceVSP_0583121–335in isoform Alpha-D3
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Alternative sequenceVSP_0583131–330in isoform Alpha-D2
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Alternative sequenceVSP_0583141–315in isoform Alpha-D1
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Alternative sequenceVSP_0583151–97in isoform Alpha-C3
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Alternative sequenceVSP_0583161–89in isoform Alpha-C2
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Alternative sequenceVSP_0583171–85in isoform Alpha-C1
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Alternative sequenceVSP_0187731–26in isoform Alpha-B and isoform Beta-B
Curator inference
Evidence & references
  • ECO:0000305
No verified residues in this structure
Alternative sequenceVSP_043908313–338in isoform 10
Published statement 1 publication
Evidence & references
No verified residues in this structure
Alternative sequenceVSP_007363451in isoform Alpha-2 and isoform Beta-2
G → GR
Published statement
Evidence & references
  • ECO:0000303 Reference:Ref.6
No verified residues in this structure
Alternative sequenceVSP_013340491–674in isoform GR-A alpha and isoform GR-A beta
Curator inference
Evidence & references
  • ECO:0000305
No verified residues in this structure
Alternative sequenceVSP_003703728–777in isoform Beta, isoform Beta-B, isoform Beta-2 and isoform GR-A beta
VVENLLNYCFQTFLDKTMSIEFPEMLAEIITNQIPKYSNGNIKKLLFHQK → NVMWLKPESTSHTLI
Published statement 1 publication
Evidence & references
No verified residues in this structure

Sequence conflicts & cautions 2

Scroll across the table for evidence and actions.

2 recorded rows

FeaturePositionDescriptionEvidenceInspect
Sequence conflict399in Ref. 7; BAD97314
R → G
Curator inference
Evidence & references
  • ECO:0000305
No verified residues in this structure
Sequence conflict754in Ref. 7; BAD97314
A → T
Curator inference
Evidence & references
  • ECO:0000305
No verified residues in this structure

Recorded secondary structure 31

Scroll across the table for evidence and actions.

31 recorded rows

FeaturePositionDescriptionEvidenceInspect
Helix416–419Helix
Evidence & references
  • ECO:0007829 PDB:7PRW
No verified residues in this structure
Turn422–424Turn
Evidence & references
  • ECO:0007829 PDB:5E69
No verified residues in this structure
Beta strand430–432Beta strand
Evidence & references
  • ECO:0007829 PDB:5E69
No verified residues in this structure
Beta strand435–437Beta strand
Evidence & references
  • ECO:0007829 PDB:5E69
No verified residues in this structure
Helix439–450Helix
Evidence & references
  • ECO:0007829 PDB:5E69
No verified residues in this structure
Beta strand458–461Beta strand
Evidence & references
  • ECO:0007829 PDB:5E69
No verified residues in this structure
Turn467–472Turn
Evidence & references
  • ECO:0007829 PDB:5E69
No verified residues in this structure
Helix474–484Helix
Evidence & references
  • ECO:0007829 PDB:5E69
No verified residues in this structure
Helix488–497Helix
Evidence & references
  • ECO:0007829 PDB:6CFN
No verified residues in this structure
Helix520–523Helix
Evidence & references
  • ECO:0007829 PDB:8A9G
No verified residues in this structure
Beta strand527–529Beta strand
Evidence & references
  • ECO:0007829 PDB:5UC1
No verified residues in this structure
Helix532–538Helix
Evidence & references
  • ECO:0007829 PDB:4UDD
No verified residues in this structure
Helix540–545Helix
Evidence & references
  • ECO:0007829 PDB:4UDD
No verified residues in this structure
Beta strand550–552Beta strand
Evidence & references
  • ECO:0007829 PDB:3K22
No verified residues in this structure
Helix556–579Helix
Evidence & references
  • ECO:0007829 PDB:4UDD
No verified residues in this structure
Helix584–586Helix
Evidence & references
  • ECO:0007829 PDB:4UDD
No verified residues in this structure
Helix589–615Helix
Evidence & references
  • ECO:0007829 PDB:4UDD
No verified residues in this structure
Beta strand617–619Beta strand
Evidence & references
  • ECO:0007829 PDB:4P6W
No verified residues in this structure
Beta strand621–624Beta strand
Evidence & references
  • ECO:0007829 PDB:4UDD
No verified residues in this structure
Beta strand627–629Beta strand
Evidence & references
  • ECO:0007829 PDB:4UDD
No verified residues in this structure
Helix631–634Helix
Evidence & references
  • ECO:0007829 PDB:4UDD
No verified residues in this structure
Helix639–655Helix
Evidence & references
  • ECO:0007829 PDB:4UDD
No verified residues in this structure
Helix660–671Helix
Evidence & references
  • ECO:0007829 PDB:4UDD
No verified residues in this structure
Beta strand673–675Beta strand
Evidence & references
  • ECO:0007829 PDB:4UDD
No verified residues in this structure
Helix683–702Helix
Evidence & references
  • ECO:0007829 PDB:4UDD
No verified residues in this structure
Beta strand704–706Beta strand
Evidence & references
  • ECO:0007829 PDB:4P6W
No verified residues in this structure
Helix708–741Helix
Evidence & references
  • ECO:0007829 PDB:4UDD
No verified residues in this structure
Helix743–745Helix
Evidence & references
  • ECO:0007829 PDB:4UDD
No verified residues in this structure
Helix751–765Helix
Evidence & references
  • ECO:0007829 PDB:4UDD
No verified residues in this structure
Helix766–768Helix
Evidence & references
  • ECO:0007829 PDB:6DXK
No verified residues in this structure
Beta strand769–771Beta strand
Evidence & references
  • ECO:0007829 PDB:5UC3
No verified residues in this structure
12

Homologs

OMA orthologs

Evolutionary relationships assigned by OMA, kept separate from sequence clusters. “1:1” describes an orthology relationship, not percentage identity.

Recorded preview of up to 12 orthologs; not an exhaustive list. Entries without a verified UniProt mapping open their OMA record.

13

Sources & References

Scientific descriptions and evidence come from the named sources. Atlas assembles the presentation and verifies residue mappings; it does not independently curate these claims.

Source dates & provenance

Recorded 2026-11-10. Source dates and identifiers are retained below.

Publications in this UniProt entry

1 · Primary structure and expression of a functional human glucocorticoid receptor cDNA.

1985 · Nature

PubMed 2867473 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA AND BETA)

Hollenberg S.M., Weinberger C., Ong E.S., Cerelli G., Oro A., Lebo R., Thompson E.B., Rosenfeld M.G., Evans R.M.

2 · The genomic structure of the human glucocorticoid receptor.

1991 · J. Biol. Chem.

PubMed 1707881 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS ALPHA AND BETA)

Encio I.J., Detera-Wadleigh S.D.

3 · Identification of rare DNA variants in mitochondrial disorders with improved array-based sequencing.

2011 · Nucleic Acids Res.

PubMed 20843780 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [GENOMIC DNA]

Wang W., Shen P., Thiyagarajan S., Lin S., Palm C., Horvath R., Klopstock T., Cutler D., Pique L., Schrijver I., Davis R.W., Mindrinos M., Speed T.P., Scharfe C.

4 · A new transcript splice variant of the human glucocorticoid receptor: identification and tissue distribution of hGR Delta 313-338, an alternative exon 2 transactivation domain isoform.

2007 · Ann. N. Y. Acad. Sci.

PubMed 17404046 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 10)

Turner J.D., Schote A.B., Keipes M., Muller C.P.

All source publications (104)
5 · Novel hyperactive glucocorticoid receptor isoform identified within a human population.

2011 · Shock

PubMed 21701417 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA); VARIANTS ASP-72; ALA-321 AND SER-766; CHARACTERIZATION OF VARIANTS ASP-72; ALA-321 AND SER-766

Tung K., Baker A.C., Amini A., Green T.L., Chew V.W., Lim D., Nguyen S.T., Yee K.S., Cho K., Greenhalgh D.G.

· Alternative splicing within the DNA binding domain creates a novel isoform of the human glucocorticoid receptor.

SEP-1993 ·

Scope & authors

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA-2)

Munroe D.G., Pang J., Taylor G.R., Lau C., Plante R.K., Zhou L.

· Reference

APR-2005 ·

Scope & authors

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA)

Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.

8 · The full-ORF clone resource of the German cDNA consortium.

2007 · BMC Genomics

PubMed 17974005 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA)

Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., Wiemann S., Schupp I.

· Reference

OCT-2003 ·

Scope & authors

NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS LYS-23 AND VAL-65

· Reference

FEB-2007 ·

Scope & authors

NUCLEOTIDE SEQUENCE [GENOMIC DNA]

11 · The DNA sequence and comparative analysis of human chromosome 5.

2004 · Nature

PubMed 15372022 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]

Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S., Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.

· Reference

SEP-2005 ·

Scope & authors

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]

Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W., Venter J.C.

13 · The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).

2004 · Genome Res.

PubMed 15489334 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA)

14 · Purification of a human glucocorticoid receptor gene promoter-binding protein. Production of polyclonal antibodies against the purified factor.

1991 · J. Biol. Chem.

PubMed 2026589 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-394

Leclerc S., Xie B.X., Roy R., Govindan M.V.

15 · Human glucocorticoid receptor gene promotor-homologous down regulation.

1991 · J. Steroid Biochem. Mol. Biol.

PubMed 1958537 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-394

Govindan M.V., Pothier F., Leclerc S., Palaniswami R., Xie B.

16 · Domain structure of human glucocorticoid receptor and its relationship to the v-erb-A oncogene product.

1985 · Nature

PubMed 3841189 ↗
Scope & authors

DOMAINS

Weinberger C., Hollenberg S.M., Rosenfeld M.G., Evans R.M.

17 · Alternatively spliced glucocorticoid receptor messenger RNAs in glucocorticoid-resistant human multiple myeloma cells.

1993 · Cancer Res.

PubMed 8358712 ↗
Scope & authors

ALTERNATIVE SPLICING (ISOFORMS GR-P; GR-A ALPHA AND GR-A BETA)

Moalli P.A., Pillay S., Krett N.L., Rosen S.T.

18 · Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans.

1995 · J. Clin. Invest.

PubMed 7769088 ↗
Scope & authors

FUNCTION (ISOFORM BETA); TISSUE SPECIFICITY (ISOFORM BETA)

Bamberger C.M., Bamberger A.M., de Castro M., Chrousos G.P.

19 · The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function.

1996 · J. Biol. Chem.

PubMed 8621628 ↗
Scope & authors

FUNCTION (ISOFORM BETA); SUBCELLULAR LOCATION (ISOFORMS ALPHA AND BETA); TISSUE SPECIFICITY (ISOFORM BETA)

Oakley R.H., Sar M., Cidlowski J.A.

20 · The glucocorticoid receptor is associated with the RNA-binding nuclear matrix protein hnRNP U.

1997 · J. Biol. Chem.

PubMed 9353307 ↗
Scope & authors

INTERACTION WITH HNRNPU

Eggert M., Michel J., Schneider S., Bornfleth H., Baniahmad A., Fackelmayer F.O., Schmidt S., Renkawitz R.

21 · Role of the Ada adaptor complex in gene activation by the glucocorticoid receptor.

1997 · Mol. Cell. Biol.

PubMed 9154805 ↗
Scope & authors

INTERACTION WITH TADA2L AND THE ADA COMPLEX; MUTAGENESIS OF PHE-191; ILE-193; LEU-194; LEU-197; TRP-213; LEU-224; LEU-225; PHE-235 AND LEU-236

Henriksson A., Almloef T., Ford J., McEwan I.J., Gustafsson J.-A., Wright A.P.H.

22 · Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex.

1998 · Nature

PubMed 9590696 ↗
Scope & authors

FUNCTION; INTERACTION WITH THE SMARCA4 COMPLEX; NCOA1; NCOA2 AND THE CREBBP/EP300 COMPLEX

Fryer C.J., Archer T.K.

23 · A nuclear action of the eukaryotic cochaperone RAP46 in downregulation of glucocorticoid receptor activity.

1999 · J. Cell Biol.

PubMed 10477749 ↗
Scope & authors

INTERACTION WITH BAG1

Schneikert J., Huebner S., Martin E., Cato A.B.C.

24 · Insertion of an amino acid in the DNA-binding domain of the glucocorticoid receptor as a result of alternative splicing.

1999 · J. Clin. Endocrinol. Metab.

PubMed 10566686 ↗
Scope & authors

ALTERNATIVE SPLICING (ISOFORMS ALPHA-2 AND BETA-2); TISSUE SPECIFICITY (ISOFORM ALPHA-2)

Rivers C., Levy A., Hancock J., Lightman S., Norman M.

25 · Steroidogenic enzyme gene expression in the human heart.

2000 · J. Clin. Endocrinol. Metab.

PubMed 10902803 ↗
Scope & authors

TISSUE SPECIFICITY

Kayes-Wandover K.M., White P.C.

26 · A new family of nuclear receptor coregulators that integrates nuclear receptor signaling through CBP.

2000 · Mol. Cell. Biol.

PubMed 10866662 ↗
Scope & authors

INTERACTION WITH NCOA6

Mahajan M.A., Samuels H.H.

27 · Regulation of expanded polyglutamine protein aggregation and nuclear localization by the glucocorticoid receptor.

2000 · Proc. Natl. Acad. Sci. U.S.A.

PubMed 10639135 ↗
Scope & authors

EFFECT ON EXPANDED POLYGLUTAMINE PROTEIN

Diamond M.I., Robinson M.R., Yamamoto K.R.

28 · Expression in hematological malignancies of a glucocorticoid receptor splice variant that augments glucocorticoid receptor-mediated effects in transfected cells.

2001 · Cancer Res.

PubMed 11358809 ↗
Scope & authors

FUNCTION (ISOFORM GR-P)

de Lange P., Segeren C.M., Koper J.W., Wiemer E., Sonneveld P., Brinkmann A.O., White A., Brogan I.J., de Jong F.H., Lamberts S.W.

29 · Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids.

2001 · J. Biol. Chem.

PubMed 11555652 ↗
Scope & authors

GLUCOCORTICOID-MEDIATED DOWN-REGULATION

Wallace A.D., Cidlowski J.A.

30 · High constitutive glucocorticoid receptor beta in human neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids.

2001 · J. Exp. Med.

PubMed 11238589 ↗
Scope & authors

REDUCTION OF CELL DEATH IN RESPONSE TO CORTICOSTEROIDS

Strickland I., Kisich K., Hauk P.J., Vottero A., Chrousos G.P., Klemm D.J., Leung D.Y.M.

31 · Molecular identification and characterization of A and B forms of the glucocorticoid receptor.

2001 · Mol. Endocrinol.

PubMed 11435610 ↗
Scope & authors

FUNCTION (ISOFORMS ALPHA AND ALPHA-B); ALTERNATIVE INITIATION; MUTAGENESIS OF MET-1 AND MET-27

Yudt M.R., Cidlowski J.A.

32 · Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance.

2001 · Proc. Natl. Acad. Sci. U.S.A.

PubMed 11381138 ↗
Scope & authors

INDUCTION (ISOFORMS ALPHA AND BETA)

Webster J.C., Oakley R.H., Jewell C.M., Cidlowski J.A.

33 · Small ubiquitin-related modifier-1 (SUMO-1) modification of the glucocorticoid receptor.

2002 · Biochem. J.

PubMed 12144530 ↗
Scope & authors

SUMOYLATION; MUTAGENESIS OF LYS-277; LYS-293 AND LYS-703

Tian S., Poukka H., Palvimo J.J., Jaenne O.A.

34 · Deciphering the phosphorylation 'code' of the glucocorticoid receptor in vivo.

2002 · J. Biol. Chem.

PubMed 12000743 ↗
Scope & authors

PHOSPHORYLATION AT SER-203 AND SER-211

Wang Z., Frederick J., Garabedian M.J.

35 · Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade.

2002 · Proc. Natl. Acad. Sci. U.S.A.

PubMed 12415108 ↗
Scope & authors

RETRACTED PAPER

Wong C.-W., McNally C., Nickbarg E., Komm B.S., Cheskis B.J.

36 · Reference

2009 · Proc. Natl. Acad. Sci. U.S.A.

PubMed 19666546 ↗
Scope & authors

RETRACTION NOTICE OF PUBMED:12415108

Wong C.W., McNally C., Nickbarg E., Komm B.S., Cheskis B.J.

37 · The origin and functions of multiple human glucocorticoid receptor isoforms.

2004 · Ann. N. Y. Acad. Sci.

PubMed 15265776 ↗
Scope & authors

REVIEW ON ALTERNATIVE SPLICING; ALTERNATIVE INITIATION

Lu N.Z., Cidlowski J.A.

38 · Distinct LIM domains of Hic-5/ARA55 are required for nuclear matrix targeting and glucocorticoid receptor binding and coactivation.

2004 · J. Cell. Biochem.

PubMed 15211577 ↗
Scope & authors

INTERACTION WITH TGFB1I1

Guerrero-Santoro J., Yang L., Stallcup M.R., DeFranco D.B.

39 · Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes.

2005 · Mol. Cell

PubMed 15866175 ↗
Scope & authors

FUNCTION (ISOFORMS ALPHA; ALPHA-B; ALPHA-C1; ALPHA-C2; ALPHA-C3; ALPHA-D1; ALPHA-D2 AND ALPHA-D3); SUBCELLULAR LOCATION (ISOFORM ALPHA-B); ALTERNATIVE INITIATION (ISOFORMS ALPHA; ALPHA-B; ALPHA-C1; ALPHA-C2; ALPHA-C3; ALPHA-D1; ALPHA-D2 AND ALPHA-D3); MUTAGENESIS OF MET-1; MET-27; MET-86; MET-90; MET-98; MET-316; MET-331 AND MET-336

Lu N.Z., Cidlowski J.A.

40 · Protein-protein interactions and transcriptional antagonism between the subfamily of NGFI-B/Nur77 orphan nuclear receptors and glucocorticoid receptor.

2005 · Mol. Endocrinol.

PubMed 15591535 ↗
Scope & authors

INTERACTION WITH NR4A3

Martens C., Bilodeau S., Maira M., Gauthier Y., Drouin J.

41 · HEXIM1 forms a transcriptionally abortive complex with glucocorticoid receptor without involving 7SK RNA and positive transcription elongation factor b.

2005 · Proc. Natl. Acad. Sci. U.S.A.

PubMed 15941832 ↗
Scope & authors

INTERACTION WITH HEXIM1

Shimizu N., Ouchida R., Yoshikawa N., Hisada T., Watanabe H., Okamoto K., Kusuhara M., Handa H., Morimoto C., Tanaka H.

42 · Functional interaction between the glucocorticoid receptor and GANP/MCM3AP.

2006 · Biochem. Biophys. Res. Commun.

PubMed 16914116 ↗
Scope & authors

INTERACTION WITH MCM3AP

Osman W., Laine S., Zilliacus J.

43 · GCUNC-45 is a novel regulator for the progesterone receptor/hsp90 chaperoning pathway.

2006 · Mol. Cell. Biol.

PubMed 16478993 ↗
Scope & authors

INTERACTION WITH UNC45A

Chadli A., Graham J.D., Abel M.G., Jackson T.A., Gordon D.F., Wood W.M., Felts S.J., Horwitz K.B., Toft D.

44 · A probability-based approach for high-throughput protein phosphorylation analysis and site localization.

2006 · Nat. Biotechnol.

PubMed 16964243 ↗
Scope & authors

IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]

Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.

45 · Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.

2008 · Mol. Cell

PubMed 18691976 ↗
Scope & authors

IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]

Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., Greff Z., Keri G., Stemmann O., Mann M.

46 · Glycogen synthase kinase 3beta-mediated serine phosphorylation of the human glucocorticoid receptor redirects gene expression profiles.

2008 · Mol. Cell. Biol.

PubMed 18838540 ↗
Scope & authors

INTERACTION WITH GSK3B; SUBCELLULAR LOCATION (ISOFORM ALPHA); PHOSPHORYLATION AT SER-404; MUTAGENESIS OF SER-404; IDENTIFICATION BY MASS SPECTROMETRY

Galliher-Beckley A.J., Williams J.G., Collins J.B., Cidlowski J.A.

47 · Glucocorticoid receptor phosphorylation differentially affects target gene expression.

2008 · Mol. Endocrinol.

PubMed 18483179 ↗
Scope & authors

PHOSPHORYLATION AT SER-203; SER-211 AND SER-226; MUTAGENESIS OF SER-211 AND SER-226

Chen W., Dang T., Blind R.D., Wang Z., Cavasotto C.N., Hittelman A.B., Rogatsky I., Logan S.K., Garabedian M.J.

48 · A quantitative atlas of mitotic phosphorylation.

2008 · Proc. Natl. Acad. Sci. U.S.A.

PubMed 18669648 ↗
Scope & authors

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-134; SER-226 AND SER-267; IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]

Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., Elledge S.J., Gygi S.P.

49 · Glucocorticoid receptor (GR) beta has intrinsic, GRalpha-independent transcriptional activity.

2009 · Biochem. Biophys. Res. Commun.

PubMed 19248771 ↗
Scope & authors

FUNCTION (ISOFORMS ALPHA AND BETA); SUBCELLULAR LOCATION (ISOFORM BETA)

Kino T., Manoli I., Kelkar S., Wang Y., Su Y.A., Chrousos G.P.

50 · Circadian rhythm transcription factor CLOCK regulates the transcriptional activity of the glucocorticoid receptor by acetylating its hinge region lysine cluster: potential physiological implications.

2009 · FASEB J.

PubMed 19141540 ↗
Scope & authors

FUNCTION (ISOFORM ALPHA); ACETYLATION AT LYS-480; LYS-492; LYS-494 AND LYS-495; MUTAGENESIS OF LYS-480; LYS-492; LYS-494 AND LYS-495; INTERACTION WITH CLOCK

Nader N., Chrousos G.P., Kino T.

51 · Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.

2009 · Sci. Signal.

PubMed 19690332 ↗
Scope & authors

IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]

Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., Rodionov V., Han D.K.

52 · The transforming acidic coiled coil (TACC1) protein modulates the transcriptional activity of the nuclear receptors TR and RAR.

2010 · BMC Mol. Biol.

PubMed 20078863 ↗
Scope & authors

INTERACTION WITH TACC1

Guyot R., Vincent S., Bertin J., Samarut J., Ravel-Chapuis P.

53 · Glucocorticoid receptor-beta and receptor-gamma exert dominant negative effect on gene repression but not on gene induction.

2010 · Endocrinology

PubMed 20484466 ↗
Scope & authors

FUNCTION (ISOFORMS ALPHA; BETA; ALPHA-2 AND 10)

Taniguchi Y., Iwasaki Y., Tsugita M., Nishiyama M., Taguchi T., Okazaki M., Nakayama S., Kambayashi M., Hashimoto K., Terada Y.

54 · Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.

2010 · Sci. Signal.

PubMed 20068231 ↗
Scope & authors

IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]

Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.

55 · Initial characterization of the human central proteome.

2011 · BMC Syst. Biol.

PubMed 21269460 ↗
Scope & authors

IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]

Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.

56 · Glucocorticoids induce mitochondrial gene transcription in HepG2 cells: role of the mitochondrial glucocorticoid receptor.

2011 · Biochim. Biophys. Acta

PubMed 21664385 ↗
Scope & authors

FUNCTION (ISOFORM ALPHA); SUBCELLULAR LOCATION (ISOFORM ALPHA)

Psarra A.M., Sekeris C.E.

57 · The 90-kDa heat-shock protein (Hsp90)-binding immunophilin FKBP51 is a mitochondrial protein that translocates to the nucleus to protect cells against oxidative stress.

2011 · J. Biol. Chem.

PubMed 21730050 ↗
Scope & authors

SUBUNIT

Gallo L.I., Lagadari M., Piwien-Pilipuk G., Galigniana M.D.

58 · Cryptochromes mediate rhythmic repression of the glucocorticoid receptor.

2011 · Nature

PubMed 22170608 ↗
Scope & authors

INTERACTION WITH CRY1 AND CRY2

Lamia K.A., Papp S.J., Yu R.T., Barish G.D., Uhlenhaut N.H., Jonker J.W., Downes M., Evans R.M.

59 · Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man.

2011 · PLoS ONE

PubMed 21980503 ↗
Scope & authors

ACETYLATION; INTERACTION WITH CLOCK

Charmandari E., Chrousos G.P., Lambrou G.I., Pavlaki A., Koide H., Ng S.S., Kino T.

60 · N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.

2012 · Proc. Natl. Acad. Sci. U.S.A.

PubMed 22814378 ↗
Scope & authors

ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1 (ISOFORMS ALPHA-B AND BETA-B); IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]

Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A., Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.

61 · Selective glucocorticoid receptor translational isoforms reveal glucocorticoid-induced apoptotic transcriptomes.

2013 · Cell Death Dis.

PubMed 23303127 ↗
Scope & authors

FUNCTION (ISOFORMS ALPHA; ALPHA-C3 AND ALPHA-D3)

Wu I., Shin S.C., Cao Y., Bender I.K., Jafari N., Feng G., Lin S., Cidlowski J.A., Schleimer R.P., Lu N.Z.

62 · Toward a comprehensive characterization of a human cancer cell phosphoproteome.

2013 · J. Proteome Res.

PubMed 23186163 ↗
Scope & authors

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-8; SER-45 AND SER-267; IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]

Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., Mohammed S.

63 · RSUME enhances glucocorticoid receptor SUMOylation and transcriptional activity.

2013 · Mol. Cell. Biol.

PubMed 23508108 ↗
Scope & authors

MUTAGENESIS OF LYS-703

Druker J., Liberman A.C., Antunica-Noguerol M., Gerez J., Paez-Pereda M., Rein T., Iniguez-Lluhi J.A., Holsboer F., Arzt E.

64 · Determinants of the heightened activity of glucocorticoid receptor translational isoforms.

2013 · Mol. Endocrinol.

PubMed 23820903 ↗
Scope & authors

FUNCTION (ISOFORMS ALPHA; ALPHA-C3 AND ALPHA-D3); MUTAGENESIS OF ASP-101; 106-GLN-GLN-107 AND 113-SER-SER-114

Bender I.K., Cao Y., Lu N.Z.

65 · An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.

2014 · J. Proteomics

PubMed 24275569 ↗
Scope & authors

PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-203; IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]

Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., Ye M., Zou H.

66 · Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli.

2014 · Proc. Natl. Acad. Sci. U.S.A.

PubMed 25114211 ↗
Scope & authors

SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-293; IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]

Impens F., Radoshevich L., Cossart P., Ribet D.

67 · Human Glucocorticoid Receptor beta (hGRbeta) Regulates Gluconeogenesis and Inflammation in Mouse Liver.

2015 · Mol. Cell. Biol.

PubMed 26711253 ↗
Scope & authors

FUNCTION (ISOFORM BETA); SUBCELLULAR LOCATION (ISOFORM BETA)

He B., Cruz-Topete D., Oakley R.H., Xiao X., Cidlowski J.A.

68 · Glucocorticoid receptor interacts with PNRC2 in a ligand-dependent manner to recruit UPF1 for rapid mRNA degradation.

2015 · Proc. Natl. Acad. Sci. U.S.A.

PubMed 25775514 ↗
Scope & authors

FUNCTION; INTERACTION WITH PNRC2

Cho H., Park O.H., Park J., Ryu I., Kim J., Ko J., Kim Y.K.

69 · Glucocorticoid receptor regulates accurate chromosome segregation and is associated with malignancy.

2015 · Proc. Natl. Acad. Sci. U.S.A.

PubMed 25847991 ↗
Scope & authors

FUNCTION (ISOFORM ALPHA); SUBCELLULAR LOCATION (ISOFORM ALPHA); TISSUE SPECIFICITY; DOMAIN; PHOSPHORYLATION AT SER-203 AND SER-211

Matthews L.C., Berry A.A., Morgan D.J., Poolman T.M., Bauer K., Kramer F., Spiller D.G., Richardson R.V., Chapman K.E., Farrow S.N., Norman M.R., Williamson A.J., Whetton A.D., Taylor S.S., Tuckermann J.P., White M.R., Ray D.W.

70 · The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding.

2016 · Nat. Commun.

PubMed 27353360 ↗
Scope & authors

INTERACTION WITH FNIP1 AND FNIP2

Woodford M.R., Dunn D.M., Blanden A.R., Capriotti D., Loiselle D., Prodromou C., Panaretou B., Hughes P.F., Smith A., Ackerman W., Haystead T.A., Loh S.N., Bourboulia D., Schmidt L.S., Marston Linehan W., Bratslavsky G., Mollapour M.

71 · Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients.

2017 · EMBO J.

PubMed 29127155 ↗
Scope & authors

IDENTIFICATION IN A COMPLEX WITH HSP90; HSP70; CDC37; PPP5C; TSC1; TSC2; AKT; CDK4 AND RAF1

Woodford M.R., Sager R.A., Marris E., Dunn D.M., Blanden A.R., Murphy R.L., Rensing N., Shapiro O., Panaretou B., Prodromou C., Loh S.N., Gutmann D.H., Bourboulia D., Bratslavsky G., Wong M., Mollapour M.

72 · Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation.

2017 · Nat. Struct. Mol. Biol.

PubMed 28112733 ↗
Scope & authors

SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-258 AND LYS-277; IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]

Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C., Nielsen M.L.

73 · Genome-wide Regulatory Roles of the C2H2-type Zinc Finger Protein ZNF764 on the Glucocorticoid Receptor.

2017 · Sci. Rep.

PubMed 28139699 ↗
Scope & authors

FUNCTION; INTERACTION WITH ZNF764

Fadda A., Syed N., Mackeh R., Papadopoulou A., Suzuki S., Jithesh P.V., Kino T.

74 · UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability.

2023 · Mol. Cell

PubMed 37478846 ↗
Scope & authors

FUNCTION; UBIQUITINATION

Tsai J.M., Aguirre J.D., Li Y.D., Brown J., Focht V., Kater L., Kempf G., Sandoval B., Schmitt S., Rutter J.C., Galli P., Sandate C.R., Cutler J.A., Zou C., Donovan K.A., Lumpkin R.J., Cavadini S., Park P.M.C., Sievers Q., Hatton C., Ener E., Regalado B.D., Sperling M.T., Slabicki M., Kim J., Zon R., Zhang Z., Miller P.G., Belizaire R., Sperling A.S., Fischer E.S., Irizarry R., Armstrong S.A., Thomae N.H., Ebert B.L.

75 · Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition.

2002 · Cell

PubMed 12151000 ↗
Scope & authors

X-RAY CRYSTALLOGRAPHY OF MUTANT SER-602 IN COMPLEX WITH NCOA2; DEXAMETHASONE AND RU-486; MUTAGENESIS OF ARG-585; ASP-590; PHE-602; PRO-625 AND ILE-628

Bledsoe R.K., Montana V.G., Stanley T.B., Delves C.J., Apolito C.J., McKee D.D., Consler T.G., Parks D.J., Stewart E.L., Willson T.M., Lambert M.H., Moore J.T., Pearce K.H., Xu H.E.

76 · The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism.

2003 · J. Biol. Chem.

PubMed 12686538 ↗
Scope & authors

X-RAY CRYSTALLOGRAPHY OF MUTANT SER-602 IN COMPLEX WITH COACTIVATOR PEPTIDE; DEXAMETHASONE AND WITH RU-486

Kauppi B., Jakob C., Faernegaardh M., Yang J., Ahola H., Alarcon M., Calles K., Engstrom O., Harlan J., Muchmore S., Ramqvist A.-K., Thorell S., Oehman L., Greer J., Gustafsson J.-A., Carlstedt-Duke J., Carlquist M.

77 · Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance.

1991 · J. Clin. Invest.

PubMed 1704018 ↗
Scope & authors

CHARACTERIZATION OF VARIANT GCCR VAL-641

Hurley D.M., Accili D., Stratakis C.A., Karl M., Vamvakopoulos N., Rorer E., Constantine K., Taylor S.I., Chrousos G.P.

78 · Cloning and expression of mutant glucocorticoid receptors from glucocorticoid-sensitive and -resistant human leukemic cells.

1993 · Cancer Res.

PubMed 8358735 ↗
Scope & authors

VARIANTS TYR-421 AND PHE-753

Powers J.H., Hillmann A.G., Tang D.C., Harmon J.M.

79 · Familial glucocorticoid resistance caused by a splice site deletion in the human glucocorticoid receptor gene.

1993 · J. Clin. Endocrinol. Metab.

PubMed 8445027 ↗
Scope & authors

VARIANT SER-363

Karl M., Lamberts S.W.J., Detera-Wadleigh S.D., Encio I.J., Stratakis C.A., Hurley D.M., Accili D., Chrousos G.P.

80 · A mutation of the glucocorticoid receptor in primary cortisol resistance.

1993 · J. Clin. Invest.

PubMed 7683692 ↗
Scope & authors

VARIANT GCCR ILE-729

Malchoff D.M., Brufsky A., Reardon G., McDermott P., Javier E.C., Bergh C.H., Rowe D., Malchoff C.D.

81 · Identification of the activation-labile gene: a single point mutation in the human glucocorticoid receptor presents as two distinct receptor phenotypes.

1993 · Mol. Endocrinol.

PubMed 8316249 ↗
Scope & authors

VARIANT PHE-753

Ashraf J., Thompson E.B.

82 · Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance.

1997 · Hum. Genet.

PubMed 9150737 ↗
Scope & authors

VARIANTS LYS-23 AND SER-363

Koper J.W., Stolk R.P., de Lange P., Huizenga N.A.T.M., Molijn G.-J., Pols H.A.P., Grobbee D.E., Karl M., de Jong F.H., Brinkmann A.O., Lamberts S.W.J.

83 · Characterization of single-nucleotide polymorphisms in coding regions of human genes.

1999 · Nat. Genet.

PubMed 10391209 ↗
Scope & authors

VARIANTS LYS-23; VAL-65 AND SER-363

Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., Lander E.S.

· Reference

1999 · Nat. Genet.

Scope & authors

ERRATUM OF PUBMED:10391209

Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L., Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q., Lander E.S.

85 · Five missense variants in the amino-terminal domain of the glucocorticoid receptor: no association with puerperal psychosis or schizophrenia.

2000 · Am. J. Med. Genet.

PubMed 10898924 ↗
Scope & authors

VARIANTS LYS-23; LEU-29; PHE-112; ASN-233 AND SER-363

Feng J., Zheng J., Bennett W.P., Heston L.L., Jones I.R., Craddock N., Sommer S.S.

86 · Characterization of two novel mutations in the glucocorticoid receptor gene in patients with primary cortisol resistance.

2001 · Clin. Endocrinol. (Oxf.)

PubMed 11589680 ↗
Scope & authors

VARIANTS GCCR HIS-477 AND SER-679

Ruiz M., Lind U., Gaafvels M., Eggertsen G., Carlstedt-Duke J., Nilsson L., Holtmann M., Stierna P., Wikstroem A.-C., Werner S.

87 · The N363S polymorphism of the glucocorticoid receptor: potential contribution to central obesity in men and lack of association with other risk factors for coronary heart disease and diabetes mellitus.

2001 · J. Clin. Endocrinol. Metab.

PubMed 11344238 ↗
Scope & authors

VARIANT SER-363

Dobson M.G., Redfern C.P.F., Unwin N., Weaver J.U.

88 · Pathologic human GR mutant has a transdominant negative effect on the wild-type GR by inhibiting its translocation into the nucleus: importance of the ligand-binding domain for intracellular GR trafficking.

2001 · J. Clin. Endocrinol. Metab.

PubMed 11701741 ↗
Scope & authors

CHARACTERIZATION OF VARIANT GCCR ASN-559

Kino T., Stauber R.H., Resau J.H., Pavlakis G.N., Chrousos G.P.

89 · A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels.

2002 · Diabetes

PubMed 12351458 ↗
Scope & authors

VARIANT LYS-23

van Rossum E.F.C., Koper J.W., Huizenga N.A.T.M., Uitterlinden A.G., Janssen J.A.M.J.L., Brinkmann A.O., Grobbee D.E., de Jong F.H., van Duyn C.M., Pols H.A.P., Lamberts S.W.J.

90 · Female pseudohermaphroditism caused by a novel homozygous missense mutation of the GR gene.

2002 · J. Clin. Endocrinol. Metab.

PubMed 11932321 ↗
Scope & authors

VARIANT PSEUDOHERMAPHRODITISM ALA-571

Mendonca B.B., Leite M.V., de Castro M., Kino T., Elias L.L.K., Bachega T.A.S., Arnhold I.J.P., Chrousos G.P., Latronico A.C.

91 · A novel, C-terminal dominant negative mutation of the GR causes familial glucocorticoid resistance through abnormal interactions with p160 steroid receptor coactivators.

2002 · J. Clin. Endocrinol. Metab.

PubMed 12050230 ↗
Scope & authors

VARIANT GCCR MET-747; ALTERED INTERACTION WITH THE COACTIVATOR NCOA2

Vottero A., Kino T., Combe H., Lecomte P., Chrousos G.P.

92 · Association of the ER22/23EK polymorphism in the glucocorticoid receptor gene with survival and C-reactive protein levels in elderly men.

2004 · Am. J. Med.

PubMed 15276593 ↗
Scope & authors

VARIANT LYS-23

van Rossum E.F.C., Feelders R.A., van den Beld A.W., Uitterlinden A.G., Janssen J.A.M.J.L., Ester W., Brinkmann A.O., Grobbee D.E., de Jong F.H., Pols H.A.P., Koper J.W., Lamberts S.W.J.

93 · The ER22/23EK polymorphism in the glucocorticoid receptor gene is associated with a beneficial body composition and muscle strength in young adults.

2004 · J. Clin. Endocrinol. Metab.

PubMed 15292341 ↗
Scope & authors

VARIANT LYS-23

van Rossum E.F.C., Voorhoeve P.G., te Velde S.J., Koper J.W., Delemarre-van de Waal H.A., Kemper H.C.G., Lamberts S.W.J.

94 · A novel point mutation in the ligand-binding domain (LBD) of the human glucocorticoid receptor (hGR) causing generalized glucocorticoid resistance: the importance of the C terminus of hGR LBD in conferring transactivational activity.

2005 · J. Clin. Endocrinol. Metab.

PubMed 15769988 ↗
Scope & authors

VARIANT GCCR PRO-773; CHARACTERIZATION OF VARIANT GCCR PRO-773; INVOLVEMENT IN GCCR; FUNCTION (ISOFORM ALPHA); INTERACTION WITH GRIP1; SUBCELLULAR LOCATION (ISOFORM ALPHA)

Charmandari E., Raji A., Kino T., Ichijo T., Tiulpakov A., Zachman K., Chrousos G.P.

95 · Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression.

2005 · J. Clin. Endocrinol. Metab.

PubMed 16030164 ↗
Scope & authors

VARIANTS LYS-23 AND SER-363; CHARACTERIZATION OF VARIANTS LYS-23 AND SER-363

Russcher H., Smit P., van den Akker E.L., van Rossum E.F., Brinkmann A.O., de Jong F.H., Lamberts S.W., Koper J.W.

96 · A novel point mutation in helix 11 of the ligand-binding domain of the human glucocorticoid receptor gene causing generalized glucocorticoid resistance.

2007 · J. Clin. Endocrinol. Metab.

PubMed 17635946 ↗
Scope & authors

VARIANT GCCR LEU-737; CHARACTERIZATION OF VARIANT GCCR LEU-737; FUNCTION (ISOFORM ALPHA); INTERACTION WITH GRIP1; SUBCELLULAR LOCATION (ISOFORM ALPHA)

Charmandari E., Kino T., Ichijo T., Jubiz W., Mejia L., Zachman K., Chrousos G.P.

97 · A novel point mutation in helix 10 of the human glucocorticoid receptor causes generalized glucocorticoid resistance by disrupting the structure of the ligand-binding domain.

2010 · J. Clin. Endocrinol. Metab.

PubMed 20335448 ↗
Scope & authors

VARIANT GCCR GLN-714; CHARACTERIZATION OF VARIANT GCCR GLN-714

Nader N., Bachrach B.E., Hurt D.E., Gajula S., Pittman A., Lescher R., Kino T.

98 · Generalized glucocorticoid resistance accompanied with an adrenocortical adenoma and caused by a novel point mutation of human glucocorticoid receptor gene.

2011 · Chin. Med. J.

PubMed 21362280 ↗
Scope & authors

VARIANT GCCR ILE-556

Zhu H.J., Dai Y.F., Wang O., Li M., Lu L., Zhao W.G., Xing X.P., Pan H., Li N.S., Gong F.Y.

99 · A novel point mutation in the DNA-binding domain (DBD) of the human glucocorticoid receptor causes primary generalized glucocorticoid resistance by disrupting the hydrophobic structure of its DBD.

2013 · J. Clin. Endocrinol. Metab.

PubMed 23426617 ↗
Scope & authors

CHARACTERIZATION OF VARIANT GCCR ALA-423

Roberts M.L., Kino T., Nicolaides N.C., Hurt D.E., Katsantoni E., Sertedaki A., Komianou F., Kassiou K., Chrousos G.P., Charmandari E.

100 · A novel point mutation of the human glucocorticoid receptor gene causes primary generalized glucocorticoid resistance through impaired interaction with the LXXLL motif of the p160 coactivators: dissociation of the transactivating and transreppressive activities.

2014 · J. Clin. Endocrinol. Metab.

PubMed 24483153 ↗
Scope & authors

VARIANT GCCR GLY-575; CHARACTERIZATION OF VARIANT GCCR GLY-575

Nicolaides N.C., Roberts M.L., Kino T., Braatvedt G., Hurt D.E., Katsantoni E., Sertedaki A., Chrousos G.P., Charmandari E.

101 · A novel mutation of the hGR gene causing Chrousos syndrome.

2015 · Eur. J. Clin. Invest.

PubMed 26031419 ↗
Scope & authors

VARIANT GCCR ARG-726; CHARACTERIZATION OF VARIANT GCCR ARG-726

Nicolaides N.C., Geer E.B., Vlachakis D., Roberts M.L., Psarra A.M., Moutsatsou P., Sertedaki A., Kossida S., Charmandari E.

102 · Functional characterization of the hGRalphaT556I causing Chrousos syndrome.

2016 · Eur. J. Clin. Invest.

PubMed 26541474 ↗
Scope & authors

CHARACTERIZATION OF VARIANT GCCR ILE-556

Nicolaides N.C., Skyrla E., Vlachakis D., Psarra A.M., Moutsatsou P., Sertedaki A., Kossida S., Charmandari E.

103 · Three novel heterozygous point mutations of NR3C1 causing glucocorticoid resistance.

2016 · Hum. Mutat.

PubMed 27120390 ↗
Scope & authors

VARIANTS GCCR SER-477; CYS-478 AND PRO-672; CHARACTERIZATION OF VARIANTS GCCR SER-477; CYS-478 AND CYS-478; FUNCTION; SUBCELLULAR LOCATION

Vitellius G., Fagart J., Delemer B., Amazit L., Ramos N., Bouligand J., Le Billan F., Castinetti F., Guiochon-Mantel A., Trabado S., Lombes M.

104 · ARGLU1 is a transcriptional coactivator and splicing regulator important for stress hormone signaling and development.

2019 · Nucleic Acids Res.

PubMed 30698747 ↗
Scope & authors

SUBCELLULAR LOCATION

Magomedova L., Tiefenbach J., Zilberman E., Le Billan F., Voisin V., Saikali M., Boivin V., Robitaille M., Gueroussov S., Irimia M., Ray D., Patel R., Xu C., Jeyasuria P., Bader G.D., Hughes T.R., Morris Q.D., Scott M.S., Krause H., Angers S., Blencowe B.J., Cummins C.L.

Wikipedia ↗

Annotation coverage audit

Every recorded UniProt comment and feature has a destination in this page. GO, Atlas annotations and interaction rows retain their separate source counts.

203 source comments and features accounted for.

View annotation inventory
Source recordTypeSection
FUNCTION:0FUNCTIONfunction
FUNCTION:1FUNCTIONfunction
FUNCTION:2FUNCTIONfunction
FUNCTION:3FUNCTIONfunction
FUNCTION:4FUNCTIONfunction
FUNCTION:5FUNCTIONfunction
FUNCTION:6FUNCTIONfunction
FUNCTION:7FUNCTIONfunction
FUNCTION:8FUNCTIONfunction
FUNCTION:9FUNCTIONfunction
FUNCTION:10FUNCTIONfunction
FUNCTION:11FUNCTIONfunction
FUNCTION:12FUNCTIONfunction
SUBUNIT:0SUBUNITinteractions
INTERACTION:0INTERACTIONinteractions
SUBCELLULAR LOCATION:0SUBCELLULAR LOCATIONlocation
SUBCELLULAR LOCATION:1SUBCELLULAR LOCATIONlocation
SUBCELLULAR LOCATION:2SUBCELLULAR LOCATIONlocation
ALTERNATIVE PRODUCTS:0ALTERNATIVE PRODUCTSsequence
TISSUE SPECIFICITY:0TISSUE SPECIFICITYexpression
TISSUE SPECIFICITY:1TISSUE SPECIFICITYexpression
TISSUE SPECIFICITY:2TISSUE SPECIFICITYexpression
INDUCTION:0INDUCTIONexpression
INDUCTION:1INDUCTIONexpression
DOMAIN:0DOMAINdomains
PTM:0PTMprocessing
PTM:1PTMprocessing
PTM:2PTMprocessing
PTM:3PTMprocessing
PTM:4PTMprocessing
POLYMORPHISM:0POLYMORPHISMdisease
DISEASE:0DISEASEdisease
MISCELLANEOUS:0MISCELLANEOUSfunction
MISCELLANEOUS:1MISCELLANEOUSfunction
MISCELLANEOUS:2MISCELLANEOUSfunction
MISCELLANEOUS:3MISCELLANEOUSfunction
MISCELLANEOUS:4MISCELLANEOUSfunction
MISCELLANEOUS:5MISCELLANEOUSfunction
MISCELLANEOUS:6MISCELLANEOUSfunction
MISCELLANEOUS:7MISCELLANEOUSfunction
MISCELLANEOUS:8MISCELLANEOUSfunction
MISCELLANEOUS:9MISCELLANEOUSfunction
MISCELLANEOUS:10MISCELLANEOUSfunction
MISCELLANEOUS:11MISCELLANEOUSfunction
MISCELLANEOUS:12MISCELLANEOUSfunction
MISCELLANEOUS:13MISCELLANEOUSfunction
MISCELLANEOUS:14MISCELLANEOUSfunction
MISCELLANEOUS:15MISCELLANEOUSfunction
SIMILARITY:0SIMILARITYdomains
CAUTION:0CAUTIONfunction
WEB RESOURCE:0WEB RESOURCEsources
feature-0Chainprocessing
feature-1Domaindomains
feature-2DNA bindingdomains
feature-3Zinc fingerdomains
feature-4Zinc fingerdomains
feature-5Regiondomains
feature-6Regiondomains
feature-7Regiondomains
feature-8Regiondomains
feature-9Regiondomains
feature-10Regiondomains
feature-11Regiondomains
feature-12Regiondomains
feature-13Compositional biasdomains
feature-14Compositional biasdomains
feature-15Compositional biasdomains
feature-16Compositional biasdomains
feature-17Compositional biasdomains
feature-18Compositional biasdomains
feature-19Modified residueprocessing
feature-20Modified residueprocessing
feature-21Modified residueprocessing
feature-22Modified residueprocessing
feature-23Modified residueprocessing
feature-24Modified residueprocessing
feature-25Modified residueprocessing
feature-26Modified residueprocessing
feature-27Modified residueprocessing
feature-28Modified residueprocessing
feature-29Modified residueprocessing
feature-30Modified residueprocessing
feature-31Modified residueprocessing
feature-32Modified residueprocessing
feature-33Modified residueprocessing
feature-34Cross-linkprocessing
feature-35Cross-linkprocessing
feature-36Cross-linkprocessing
feature-37Cross-linkprocessing
feature-38Cross-linkprocessing
feature-39Cross-linkprocessing
feature-40Cross-linkprocessing
feature-41Alternative sequencesequence
feature-42Alternative sequencesequence
feature-43Alternative sequencesequence
feature-44Alternative sequencesequence
feature-45Alternative sequencesequence
feature-46Alternative sequencesequence
feature-47Alternative sequencesequence
feature-48Alternative sequencesequence
feature-49Alternative sequencesequence
feature-50Alternative sequencesequence
feature-51Alternative sequencesequence
feature-52Natural variantdisease
feature-53Natural variantdisease
feature-54Natural variantdisease
feature-55Natural variantdisease
feature-56Natural variantdisease
feature-57Natural variantdisease
feature-58Natural variantdisease
feature-59Natural variantdisease
feature-60Natural variantdisease
feature-61Natural variantdisease
feature-62Natural variantdisease
feature-63Natural variantdisease
feature-64Natural variantdisease
feature-65Natural variantdisease
feature-66Natural variantdisease
feature-67Natural variantdisease
feature-68Natural variantdisease
feature-69Natural variantdisease
feature-70Natural variantdisease
feature-71Natural variantdisease
feature-72Natural variantdisease
feature-73Natural variantdisease
feature-74Natural variantdisease
feature-75Natural variantdisease
feature-76Natural variantdisease
feature-77Natural variantdisease
feature-78Natural variantdisease
feature-79Natural variantdisease
feature-80Mutagenesisdisease
feature-81Mutagenesisdisease
feature-82Mutagenesisdisease
feature-83Mutagenesisdisease
feature-84Mutagenesisdisease
feature-85Mutagenesisdisease
feature-86Mutagenesisdisease
feature-87Mutagenesisdisease
feature-88Mutagenesisdisease
feature-89Mutagenesisdisease
feature-90Mutagenesisdisease
feature-91Mutagenesisdisease
feature-92Mutagenesisdisease
feature-93Mutagenesisdisease
feature-94Mutagenesisdisease
feature-95Mutagenesisdisease
feature-96Mutagenesisdisease
feature-97Mutagenesisdisease
feature-98Mutagenesisdisease
feature-99Mutagenesisdisease
feature-100Mutagenesisdisease
feature-101Mutagenesisdisease
feature-102Mutagenesisdisease
feature-103Mutagenesisdisease
feature-104Mutagenesisdisease
feature-105Mutagenesisdisease
feature-106Mutagenesisdisease
feature-107Mutagenesisdisease
feature-108Mutagenesisdisease
feature-109Mutagenesisdisease
feature-110Mutagenesisdisease
feature-111Mutagenesisdisease
feature-112Mutagenesisdisease
feature-113Mutagenesisdisease
feature-114Mutagenesisdisease
feature-115Mutagenesisdisease
feature-116Mutagenesisdisease
feature-117Sequence conflictsequence
feature-118Sequence conflictsequence
feature-119Helixsequence
feature-120Turnsequence
feature-121Beta strandsequence
feature-122Beta strandsequence
feature-123Helixsequence
feature-124Beta strandsequence
feature-125Turnsequence
feature-126Helixsequence
feature-127Helixsequence
feature-128Helixsequence
feature-129Beta strandsequence
feature-130Helixsequence
feature-131Helixsequence
feature-132Beta strandsequence
feature-133Helixsequence
feature-134Helixsequence
feature-135Helixsequence
feature-136Beta strandsequence
feature-137Beta strandsequence
feature-138Beta strandsequence
feature-139Helixsequence
feature-140Helixsequence
feature-141Helixsequence
feature-142Beta strandsequence
feature-143Helixsequence
feature-144Beta strandsequence
feature-145Helixsequence
feature-146Helixsequence
feature-147Helixsequence
feature-148Helixsequence
feature-149Beta strandsequence
feature-150Modified residueprocessing
feature-151Modified residueprocessing